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In modern drug discovery practices, drug leads are screened / designed against a 
pre-selected drug target. As a prerequisite step, target identification directs further 
research and developments. It has become increasingly important and received more 
and more attention from researchers.  
This work begins with the development of the Therapeutic Target Database (TTD), 
which provides a comprehensive information source of known therapeutic targets and 
serves as a basis for the development of other in silico tools. A relational data model 
was designed specifically for this database which aims to maximize the ability to 
accommodate future extensions and facilitate the integration of information. 
Rapid discovery of new therapeutic targets is also very important as it may not only 
introduce more efficient therapeutic targets for certain diseases, but also increase the 
flexibility in designing of novel therapeutic intervention strategies by exploiting the 
synergies between known and newly discovered targets. With this database, statistical 
learning approaches are explored in rapid drug target discovery. Our results showed 
that support vector machine, a novel statistical learning approach, may be useful in the 
prediction of drug-target like proteins in human genome.  
Besides more effective therapeutic targets, delicate therapeutic mechanisms 
involving multiple cooperating targets may also help to improve the treatment 
effectiveness. Novel therapeutic mechanisms discovered from studies of herbal 
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medicines have routinely been used in new drug discovery. However, the insufficient 
mechanistic understanding of Medicinal Plants (MPs) hinders the efforts of developing 
new drugs based on the novel therapeutic mechanisms of MP ingredients. With known 
drug target information, virtual screening technologies are explored in the rapid 
analysis of the therapeutic mechanisms of effective herbal medicines. While a number 
of methods bear the potential in this application, our testing results on an extended 
docking method, the inverse docking approach, suggests its usefulness in facilitating 
the rapid analysis of the therapeutic mechanisms of effective herbal medicines.  
Currently, computer aided drug design approaches mainly focus on the structure 
properties of a drug target and its possible binder to find or design a chemical that 
could bind the target tightly. However, these approaches based on the “lock and key” 
principle neglect the important processes prior to and after drug–receptor interactions. 
Therefore, the success rate of new drug candidates is still low. Introducing the 
consideration of mechanisms of drug action into the early stages of drug design 
process becomes a popular idea among drug design experts. In this regard, the drug 
target directed in silico approaches discussed in this work can be regarded as part of 
the efforts toward therapeutic mechanism based drug design. Novel approaches 
introducing the consideration of ADME profile, potential toxicity effects and other 
important factors into the early stages of drug discovery process would be interesting 
topics that follow this work. 
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1.1 Introduction to drug discovery 
 The search for new, effective and safe drugs has become increasingly 
sophisticated. Two pronounced characteristics marked the modern age of the 
pharmaceutical industry: “competitiveness” and “high cost”. Driven by the high 
exclusive marketing profit, competition between pharmaceutical companies is much 
more intensive than before. Moreover, it is a competition by innovation [1], as 
highlighted by the title of an article in a research management journal: “’Innovate or 
die’ is the first rule of international industrial competition” [2].  
Besides the profit, the cost of discovering a new drug is also very high. Recent 
statistics shows that it would take 10-12 years, 200-350 million U.S. dollars to 
discover a new drug [3]. And this cost has been growing at a rate of 20% per year [3]. 
To alleviate this problem, efforts have been directed to reduce the cost and time span 
needed for the discovery of a new drug. In consideration of the current patent 
protection period of 20 years for new drugs, any advance in getting a drug out more 
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quickly is desirable. In addition to its great contribution to the improvement of our life 
qualities, it is enormously profitable. If the research and development (R&D) stage 
took 10 years, the exclusive marketing period would only have 10 years left. If the 
R&D time were to be shortened for 2 or 3 years, not only a big amount of R&D 
funding could be saved, but also a longer precious exclusive marketing period would 
be rewarded. 
More and more computer approaches are now being developed to reduce the 
cost and cycle time for discovering a new drug. In order to appreciate the drug target 
directed in silico approaches in drug discovery and development, the background of 
drug discovery is necessary to be introduced first. 
1.1.1 History of drug discovery 
Around the period from 1872 to 1874, as a medical student in the laboratory of 
the anatomist Wilhelm Waldeyer at the University of Strasbourg in Germany, Paul 
Ehrlich observed that certain dyes showed selective affinity to biological tissues. This 
observation led Ehrlich to postulate the “chemoreceptor hypothesis” [4]. This 
hypothesis argued that certain chemoreceptors on parasites, micro-organisms, and 
cancer cells would be different from analogous structures in host tissues, and that 
these differences could be exploited therapeutically. This idea gave rise to the birth 
of chemotherapy, laid the ground in immunology and pharmacology, and 
subsequently led to the drug discovery practices. 
In the late 19th and early 20th century, the development of analytical chemistry 
methodologies such as chromatography, mass spectrometry, Nuclear Magnetic 
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Resonance (NMR) spectrometry [5,6] and purification techniques used in organic 
chemistry [7-9] had been proved fruitful in the purification and characterization of 
active ingredients form medicinal plants. For instance, morphine [10] was first 
isolated from opium extract in 1815 and papaverin [11] in 1848. Another prominent 
example is the discovery of penicillin [12] as an antibiotic by Alexander Fleming in 
1929 from a penicillium mold. The discovery of penicillin had opened a door for other 
scientists to search for other chemically related derivatives as well as new antibiotics. 
Since then, many drug companies established their own research units to search for 
drugs that exerted other pharmacological or chemotherapeutic properties. 
The advances in biochemistry [13] also influenced drug discovery significantly. 
Many drugs were found to exert their effects by interacting with biological 
macromolecules such as enzymes, DNA (deoxyribonucleic acid) or RNA (ribonucleic 
acid), glycoproteins, hormones, receptors and transcription factors, which are 
regarded as drug targets. It is also well understood that in most of the cases, drugs 
exert their functions by interacting with their targets mainly by non-covalent bonds 
such as van der Waals interactions, the same hydrogen bond interactions, and 
electrostatic interactions [14]. Only in few instances are covalent interactions formed 
[15]. 
1.1.2 Modern drug discovery 
After more then 150 years of development, the discovery and development of a 
new drug is still a long and expensive process while it has become much more 
competitive. At present, new agents discovered not only need to show the desired 
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therapeutic effects, but also need to be demonstrably better than existing drugs in 
terms of less side effects and higher efficacy. The development and improvement of 
drug discovery technologies is indispensable in order to win the competition of 
innovation [1] in the modern pharmaceutical industry. 
As illustrated in Fig 1.1, a typical new drug discovery process starts from target 
identification, which is followed by the search for drug leads and then clinical trials.  
 
 
The step of lead discovery is considered a bottle-neck of the drug discovery 
process [16,17]. In the past, leads were mainly discovered by random screening of a 
large chemical library. The sources of chemicals can be diverse such as active 
ingredients of natural products, derivatives of existing drugs, or even random 
synthesized chemicals. Most large pharmaceutical companies have their own 
corporate libraries, which contain the chemicals accumulated from years of efforts. It 
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Figure 1.1 Stages of the new drug discovery process 
Target 
identification
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10-20 thousand of chemicals [3]. Therefore, the efficiency of mere random screening 
is very low.  
The increasingly better understanding of the drug-target interaction mechanism 
and rapid advances in biochemistry and organic chemistry lead to the advent of 
computer aided drug design (CADD) [18-24], which aims to help the rapid and 
efficient discovery of drug leads. These approaches can be grouped into three 
categories according to their different strategies. 
1.1.2.1 Combinatorial chemistry based approaches 
One way to improve the efficiency of lead discovery is to reduce the average 
time and cost required for individual target-chemical binding affinity assay. This idea 
is fulfilled by the emergence of combinatorial chemistry [25] in the 1990s. 
Combinatorial chemistry provides a tool to do systematic screening of a large 
number of small chemicals. Building blocks are first designed by computer software 
using molecular modeling techniques. A combinatorial chemical library is then 
synthesized or virtually synthesized maximizing the molecular diversity [26,27]. With 
the help of high-throughput screening technologies, the average time and cost for 
screening an individual compound in a large chemical library are significantly 
reduced [28]. Combinatorial chemistry is mainly based on wet-lab experiments and 
is not within the scope of this work. Therefore, it will not be covered in detail here. 
1.1.2.2 Receptor structure based drug design 
Another way to improve the efficiency of lead discovery is to focus on those 
chemicals that are more possible to be drug leads, which is fulfilled by rational drug 
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design approaches. 
In case that a specific drug target and its 3D structure are known, receptor 
structure based drug design can be conducted. With the progressing of molecular 
biology, X-ray crystallography and NMR techniques, the structures of many drug 
targets have been determined [29]. More structures of drug targets can be modeled 
using homology-based methods [30]. Based on the 3D structure of the 
macromolecule receptor, molecular modeling techniques [23] are first applied to infer 
the mechanism of interaction between the target and its ligands. The essential 
structural features of the target are then summarized from the mechanism, such as 
electrostatic interaction areas, hydrophobic interaction areas, hydrogen bond donors 
and acceptors. Base on these features, rational drug design methods can then be 
used to obtain possible starting structures for leads optimization. There are two kinds 
of such methods, namely the “whole-molecule method” and the “connection 
method”. 
The “whole-molecule method” mainly relies on the molecular docking technique 
[31-38]. It searches an entire 3D structure database of small molecules to find 
putative drug leads for a specific therapeutic target. In this course, docking single or 
multiple small molecules in single or multiple conformations to the receptor binding 
sites of the target is attempted, in order to find the best putative ligand-receptor 
complex conformation. Testing results on a number of flexible docking algorithms 
have shown that these algorithms are capable of finding binding conformations close 
to experimentally determined ones [39-41]. Based on geometric and chemical 
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complementarities, a score is given to each putative ligand-receptor complex to 
reflect the “expected” binding affinity. Chemicals are considered as potential drug 
leads if their scores pass certain threshold. 
 Connection methods work progressively like building a house by bricks. 
Functional groups that best interact with important receptor sites are first placed on 
the receptor, and then they gradually “grow” to a full molecule. This is like the greedy 
search method often used in mathematical optimizations. Many drug design tools 
have been developed implementing this idea, such as CLIX [42], LUDI [43], CAVEAT 
[44], LEGEND [45], and MCDNLG [46]. 
 The receptor structure based drug design strategy has showed more and more 
significance in new drug discovery [47-54]. There are many successful examples, 
one of which can be found in Inviraser [51], approved as an anti-HIV drug by FDA 
(Food and Drug Administration, USA) in 1995. This drug was developed by 
Hoffmann La Roche co. Ltd. It was the first HIV protease inhibitor approved by FDA. 
1.1.2.3 Chemical structure activity relationship based drug design 
In the case when some effective drugs / ligands of a target are known, Structure 
Activity Relationship (SAR) based drug design can be performed. Usually, by 
studying a series of small chemicals that have similar pharmacological effects 
through the same mechanism, Quantitative Structure Activity Relationship (QSAR) / 
3D-QSAR models [55-59] are constructed to reflect the relationship between their 
activities and their quantitative structure properties. Then the QSAR / 3D-QSAR 
models can be used to screen a chemical library for potential drug leads, as well as 
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provide theoretical guidance on lead structure optimization. Furthermore, by means 
of conformation analysis and molecular modeling, 3D pharmacophore models [60-62] 
can be inferred from the SAR models. Based on the pharmacophore models, 3D 
chemical structure database queries [63] can be performed to obtain possible drug 
leads. It is also possible to optimize lead structures according to the 3D 
pharmacophore models [64,65].  
The key step in this strategy is the derivation of QSAR/3D-QSAR models. In the 
year of 1868, Crum-Brown and Fraser published the first equation in the field of 
QSAR (Equation 1.1), which set forth the idea that the biological activity of a 
compound Φ  is a function of its structure properties C [66].  
)(Cf=Φ                            Equation 1.1 
Nearly one century later, Hansch and Fujita [67,68] discovered the extra 
thermodynamic approach (also called Hansch approach, Equation 1.2), which says 
that the activity of a drug is related to, in a linear model, three descriptors, namely 
the hydrophobicity parameter π  or Plg , the electrostatic parameter σ , and the 
stereo parameter sE .  
ConstcEbPaC s ++++= ...lg1lg σ   ( RConstcba ∈,,, )   Equation 1.2 
Modern QSAR / 3D QSAR studies use much more complicated descriptors to 
capture the structure features of small chemicals, such as hydrophobicity 
parameters [69,70], electrostatic parameters (such as Hammett parameter σ [71], 
field parameter F and resonance parameter R [72]), stereo parameters (such as Taft 
constant [73], STERIMOL parameters[74]), indicator variables (such as molecular 
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topological index [75,76]) and computed theoretical  parameters (such as electron 
structure parameters, force field parameters and free energy related parameters). 
Also, much more complicated statistical learning algorithms have been explored in 
QSAR studies to construct better models, which include partial least squares (PLS) 
[77,78], principal component analysis (PCA) [79], genetic algorithm (GA) [80,81], and 
artificial neural network (ANN) [82-86]. The competition for the best descriptors and 
the best models are still far from the end. 
Small molecule structure activity relationship based drug design is one of the 
most “classical” approaches used in drug design. One successful example of the 
classic Hansch-Fujita QSAR method can be found in the development of the 
anti-cancer drug asulacrine (CT921) [87]. In the QSAR research, Denny et. al. 
focused not only on the DNA-binding ability of the chemical, but also tried to optimize 
the solubility and pKa . So far, asulacrine had entered phase II clinical trial and 
possessed a good prospect in the treatment of breast cancer [88]. 
 
1.2 Therapeutics target and drug discovery 
The above mentioned technologies are powerful tools in new drug discovery. 
However, their successes are built on an appropriate selection of therapeutic 
intervention strategy and therapeutic targets. As the initial step in the chain process 
of drug discovery, this step shall be paid full attention. 
1.2.1 Information resources of therapeutic targets 
A comprehensive knowledge database on therapeutic targets summarizing 
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known drug target information will undoubtedly help the selection of therapeutic 
targets and the design of therapeutic intervention strategies that explore the 
synergies between known targets [89]. However, the information about known drug 
targets is still scattered among the millions of available references. Work needs to be 
done in order to collect and sort the drug target information. We therefore directed 
our effort in developing a database of known therapeutic targets with the aim to 
facilitate convenient access of the relevant information and knowledge discovery 
[90]. 
All the information in the Therapeutic Target Database (TTD) was manually 
collected from available literature data with the help of a few simple automated text 
retrieval programs. A relational data model [91] was designed specifically for this 
database with deliberate effort to maximize the ability to accommodate future 
extensions and facilitate the integration of information. The database was finally 
implemented on an Oracle 9i DBMS (DataBase Management System) [92] and a 
public accessible web interface was built using the Active Server Page (ASP) 
technology [93,94]. The database schema and web interface of TTD has been 
extended to develop two other databases -- Drug Adverse Reaction Target (DART) 
database and drug Absorption, Distribution, Metabolism, Excretion Associated 
Protein (ADME-AP) database. 
1.2.2 Discovery of novel therapeutic targets 
Besides a central information source for known targets, rapid discovery of new 
therapeutic targets is also very important. It may not only introduce more efficient 
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therapeutic targets, but also increase the flexibility in designing novel therapeutic 
intervention strategies by exploiting the synergies between known and newly 
discovered targets. The discovery of new targets that are sufficiently robust to yield 
marketable therapeutics is an enormous challenge [95,96]. The completion of human 
genome project [97] brought a new opportunity for target discovery by the way of 
systematic genome scale screening.  
Conventional approaches of target discovery are mainly disease-dependent, 
such as screening of disease-derived cell lines, analysis of crucial elements of 
disease-affected pathways, examination of gene transcript levels and protein 
expression levels of cells in disease status [95]. These methods involve heavy 
wet-lab experiments as well as domain expertise in respective diseases and 
therefore are difficult to be applied in the genome scale target identification. Hence, 
rapid in silico disease-independent target discovery methods are desired. 
The search for novel targets is, to a certain degree, similar to the search for 
novel drug leads in rational drug design. For example, the ligands of a certain protein 
share some common structural features. In a typical QSAR study, a statistical model 
is first constructed to learn the common features represented by a proper set of 
descriptors, and then used to predict new ligands of this protein according to their 
descriptors. Proteins targeted by drugs are belonging to a unique group among all 
others [89]. An appropriate set of descriptors may also reflect some common 
features they share, which might be used to identify new potential drug targets. This 
leads to the study on the prediction of drug-target like proteins by statistical learning 
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methods described in Chapter 3. 
With the known drug targets as examples, we explored the usefulness of 
statistical learning methods [98-103] in the prediction of drug-target like proteins 
based on protein sequences, which may have the potential to be applied in genome 
scale drug target screening. Specifically, our studies on one statistical learning 
method, support vector machine [104], showed that it is able to train a statistical 
model reasonably well to facilitate the identification of potential new drug targets in 
the human genome. Its overall prediction accuracy is nearly 90% high and the 
prediction accuracy may be further improved by new developments in learning 
algorithms, descriptors, and pre-processing techniques. 
1.2.3 Study of novel therapeutic mechanisms 
Proven efficient therapeutic intervention strategies are of great value to the 
designing of new therapeutic intervention strategies. Medicinal plants serve as a 
good repository for clinical effective drug mechanisms [105] as they have been 
explored therapeutically in traditional medicines for hundreds of years and have 
already been used as an important source for potential drug leads in modern drug 
discovery [106-108]. It was known that 1/3 of the currently available drugs were 
developed from herbal ingredients [108]. However, there are lots of effective herbal 
medicines that do not have their therapeutic mechanisms understood yet. 
Insufficient knowledge about the molecular mechanism of these medicinal plants 
limits the scope of their application and hinders the effort to design new drugs using 
the therapeutic principles of herbal medicines. This problem can be partially 
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alleviated if efficient methods for rapid identification of protein targets of herbal 
ingredients can be introduced. 
Efforts have been directed at developing efficient computer methods facilitating 
the target identification for small molecules. The rational drug design technologies 
developed for searching drug leads for a certain target [41,58,109,110] may also be 
inversely used for the identification of therapeutic targets of effective herbal 
medicines with unknown mechanisms of action. For example, the virtual binding test, 
originally designed to search for protein binders, shows a good potential to be 
extended to analyze novel therapeutic mechanisms of herbal medicines. One 
computer program, INVDOCK [111], has been developed to search the therapeutic 
target database for therapeutic targets of active herbal ingredients. We selected nine 
herbal ingredients to evaluate usefulness of INVDOCK in the identification of 
therapeutic targets of medicinal herbal ingredients [112]. The results showed that the 
majority of INVDOCK identified therapeutic targets and their associated therapeutic 
effects have been confirmed or implicated by previous studies, which suggests the 
potentiality of in silico methods in facilitating the study of molecular mechanisms of 
medicinal plants. 
 
1.3 Thesis outline 
As introduced above, although the problems addressed in this thesis are focused 
on drug targets, the techniques used in this work span several relatively independent 
areas, namely information technology, statistical learning and molecular modeling. 
Chapter 1: Introduction   14
As a multi-disciplinary work, two distinct audiences are addressed, one of specialists 
in pharmacology, the other of specialists in computer science or bioinformatics. 
Despite the fact that either group may find certain sections of this work elementary, 
such sections are included to cover backgrounds for the benefit of individuals from 
outside of the given field. 
The multi-disciplinary nature of this work requires a slightly different thesis 
organization. Because the approaches used in different chapters are virtually 
dissimilar and independent, these methods and their backgrounds are discussed in 
their respective chapters to maintain the best coherency. This thesis is divided into 
five chapters. Chapter 1 introduces the general background of this work. Chapter 2, 
therapeutic target database development, describes the effort to establish a public 
accessible information source of known therapeutic targets. The attempt to construct 
a statistical model for the prediction of drug-target like proteins is detailed in Chapter 
3. The study of the molecular mechanisms of medicinal plants by an in silico 
approach is documented in chapter 4. And finally, a summary of this work is 
presented in Chapter 5. 
 




Therapeutic target database development 
 
This chapter describes our work in developing a publicly accessible drug target 
database, Therapeutic Target Database (TTD), which provides information about the 
known protein and nucleic acid therapeutic targets together with the targeted 
diseases / conditions, their pathway information and those corresponding drugs / 
ligands directed at each of these targets. An ontology-like database structure is 
devised to manage the drug target information as well as maintaining the maximum 
flexibility to accommodate new interests in drug mechanisms. Web interfaces built 
on this database structure inherits this flexibility. The work of TTD has been extended 
to the construction of two other drug mechanism information databases, namely 
Drug Adverse Reaction Database (DART) and drug Absorption Distribution 
Metabolism and Excretion Associated Protein database (ADME-AP). 
 
2.1 Introduction 
Pharmaceutical agents generally exert their therapeutic effects by binding to 
some particular protein or nucleic acid targets [89,113]. So far, hundreds of proteins 
and nucleic acids have been explored as therapeutic targets [89]. Rapid advances in 
genetic [114,115], structural [29,30] and functional [116] understandings of disease 
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related genes and proteins not only raise strong interest in the search for new 
therapeutic targets, but also promote the study of various aspects of known targets 
including the molecular mechanisms of their binding agents, related adverse effects 
[117], and pharmacogenetic implications [118], etc. The knowledge gained from such 
studies is important in facilitating the design of more potent, less toxic, and 
personalized drugs. Development of advanced computational methods for 
bioinformatics [119], molecular modeling [120], drug designing and pharmacokinetics 
analysis [54,56,111] increasingly uses known therapeutic targets and drugs to refine 
and test algorithms and parameters. Therefore, a database that provides 
comprehensive information about therapeutic targets will be helpful in catering to the 
needs and interests of the relevant communities in general and those unfamiliar with 
a specific therapeutic target in particular.  
Database development is one of the major concerns in the field of bioinformatics 
[121]. The motivation for design and development of bioinformatics databases 
comes from the challenge of bridging the gap between knowledge and their efficient 
management (storage, retrieval and processing) in biomedical sciences. It is said 
that in the post-genomic area, the annotation of sequences would be a major 
direction of bioinformatics [121-123]. The development of specialized domain 
knowledge databases such as TTD can be regarded as part of this effort.  
In order to provide a background for readers who are not familiar with biological 
databases, a brief history of bioinformatics with the focus on publicly accessible 
databases is briefly introduced below. 
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Although the term bioinformatics was first coined in the 1980s, the idea of using 
computers to store and manage biological data was actually initiated by X-ray protein 
crystallographers in the 1960’s [124]. Their early work led to the establishment of the 
first bioinformatics database in 1971:  Brookhaven National Laboratory’s Protein 
Data Bank (PDB), a database of 3D protein structures [125].  
However, the advent of what we call bioinformatics today was mainly driven not 
by X-ray crystallographers but by the development of improved automatic DNA 
sequencing technology [126,127]. Prior to these Nobel-prize winning developments, 
it would take a laboratory at least two months to sequence just 150 nucleotides. By 
the end of 1970s, it was possible to sequence around 200 bases per day. Owing to 
the introduction of fluorescence labeling technology [128] and multiplexed capillary 
electrophoresis [129-131], fully automated DNA sequencers soon appeared. Now 
with instruments such as the ABI 3700 or the Pharmacia Megabase 500, it is 
possible to sequence 500,000 bases per day on a single machine. Today, companies 
such as Celera, Incyte, Monsanto and others are capable of sequencing up to 100 
million bases a day. 
Because of these new technologies, DNA sequencing activities became heavily 
dependent on computer software for assembling, storing and managing DNA 
sequence data [132-135]. The rapid accumulation of DNA sequence data also 
stimulated much interest in the development of statistical methods and computer 
programs for analyzing DNA and protein sequences [136-139]. The need for 
computational tools was especially amplified with the launch of the Human Genome 
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Project in 1990 [140]. Beginning as a 15 year effort coordinated by the U.S. 
Department of Energy and the National Institutes of Health, its ultimate goal is to 
map sequence and identify all 30,000+ genes in the human genome. The first draft 
of human genome was completed on June 25, 2000 and released publicly on Feb 15, 
2001 [141-143]. It is expected that a finished version of human genome will be 
released very soon. By then it is also expected that the genomes of many other 
organisms will have been sequenced. Not only has bioinformatics played a key role 
in handling, sorting and storing this genomic information, it is also expected to help 
with the new challenges ahead in inferring gene and protein functionality [122,123], 
which is critical in the advances of biomedical and pharmaceutical sciences. 
Another stimulus for the rapid advances of bioinformatics has been the 
spectacular growth in computer technology [144]. It is uncannily predicted by Gordon 
Moore in 1965: “The processing speed of a microchip will double about every 18 
months”. Today, this trend still holds true and it is know as the Moore’s Law [145]. 
Such rapid rate of computer hardware development has led to the creation of a 
thriving computer industry that delivers very high performance machines at relatively 
low prices. This in turn has led to the ubiquitous distribution of desktop computers, 
allowing easy access to computational tools among biologists and drug designers. 
Also, there is another significant reason for the rapid growth in computer usage 
among biologists and pharmaceutical researchers, which is the emergence of the 
“Information Superhighway” – Internet [146-148]. Originally developed in 1969 by the 
U.S. Department of Defense for research in communication networkings, ARPANET 
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[149] (as it was called then) grew from a text-only messaging system to a graphical, 
interactive communication medium, enabling rapid information exchange [150,151]. 
By 1993, Internet uses exploded with the introduction of browsers such as Mosaic 
and Netscape. These web browsers and their special communication language, 
HTML (Hypertext Markup Language) [152], have greatly facilitated the access and 
communication between individuals, research labs, universities and other large 
research organizations. Taking advantages of the information highway, centralized 
biological databases have been established. Dedicated bioinformatics web servers 
such as EXPASY (http://www.expasy.org) [153] and National Center for 
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov) [154] heralded the 
establishment of the Internet as the primary means of communication among 
biological and pharmaceutical researchers, causing the field of bioinformatics to truly 
take off. So far, there are more than 500 published biological databases and this 
number keeps growing annually [155-157].  
While many databases have been built for knowledge exchange and discovery 
with different focuses, a public database focusing on therapeutic target information 
has not yet been established. Although probably all the proteins and nucleic acids 
targeted by drugs are in other databases, they are not specified as therapeutic 
targets and  it is troublesome for researchers to search for information across 
multiple databases. Moreover, because of the different focuses of these databases, 
the annotations they provide may not be so relevant to drug discovery. A database 
focusing on therapeutic targets are therefore needed as a basic tool in 
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pharmaceutical sciences to support the multi-disciplinary effort of modern drug 
discovery. For example, with comprehensive drug target information, in silico 
approaches may be applied to facilitate the discovery of novel therapeutic targets 
and therapeutic mechanisms, which are discussed later in the next two chapters. 
 
2.2 Collection of therapeutic target information 
A survey of modern drug design approaches reveals that the information on 
three types of molecules is of great interest to relevant communities: drug targets 
(proteins or nucleotides), drugs / chemicals that bind these targets and natural 
ligands of these targets [48,50,54,56,74,113,158].  
Drug targets are the primary focus of the database. Important properties of a 
target include its synonyms, related diseases and pathways. Unlike small chemicals, 
there is no systematic naming protocol designed for macromolecules. Contemporary 
naming for proteins and genes are not unified. For example, prostaglandin H2 
synthase, a well known therapeutic target for inflammation, is also known as 
cyclooxygenase [159], while the two names bear no obvious morphological similarity. 
The prevailing heterogeneous naming in literature makes it necessary to enforce a 
standardized or systematic nomenclature for drug targets. Therefore, a unique 
identifier needs to be assigned to each target, which is also the solution adopted by 
major sequence databases such as SWISS-PROT and NCBI. In TTD, the most 
popularly used target name is chosen for each target and other names of the protein 
are stored as its synonyms. The therapeutic effects achieved through the regulation 
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of target activity are no doubt the most important feature of a therapeutic target. To 
understand the therapeutic effects, this regulation of target activity shall be examined 
in the complex pathways in the host organisms [160]. The pathway information is 
therefore very useful to a variety of applications such as finding alternative 
therapeutic targets, designing a therapeutic intervention strategy which involves 
multiple co-operating targets, and analyzing potential drug-drug interactions. As 
introduced in Chapter 1, receptor 3D structure based approaches require the 3D 
structures of target molecules. In case that the 3D structure of a target has not been 
resolved, the primary sequence of the target may be used to derive its 3D model. 
Therefore, cross reference to PDB, the protein 3D structure database, and 
SWISS-PROT, a major protein sequence database with wealthy annotation, shall be 
established whenever possible.  
A new drug discovery process can also start from the structural information of 
the small molecules that bind a certain target. In this case, a series of known binders 
of a target are analyzed to derive a structure activity relationship model. Information 
on drugs, investigational drugs, and other chemicals that have activities on a certain 
target is therefore very important. A target may have multiple binding sites [161-164]. 
Different drugs may bind to different binding sites of a target and exert different 
regulatory effects on the target activity. Therefore, drugs of different types may have 
different binding sites and shall be differentiated as their structure activity 
relationship may be different.  
Drug binding is competitive in nature [165-169]. This binding competitiveness is 
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an important factor in drug design. Natural ligands of drug targets are prevailing 
competitors. A drug is less likely to be effective if it binds to its receptor 
non-competitively against the natural ligands of the receptor. Thus the information on 
natural ligands that can bind to the known drug targets is also desirable. 
Drugs and natural ligands are generally small chemicals. Although there is a 
standard IUPAC (International Union of Pure and Applied Chemistry) name for every 
small chemical, they are not the most widely used ones. Therefore, a unique 
identifier is assigned for drugs and natural ligands in the database. With the help of 
IUPAC names, it is much easier to identify the synonyms of the same chemical. In 
this database, the molecular formula, molecular weight, CAS RN (Chemical Abstract 
Service Registration Number, an identification number given to each registered 
chmeical), and chemical classification of a drug or natural ligand are provided. 
Because the information collected is mostly reported in experiments using 
different methodologies, equipment and reagents, the heterogeneous quality of data 
in this database requires that the references to the original information sources be 
provided. The citation of the literature is therefore provided wherever applicable.  
 With the rapid advances in new drug discovery, more and more information 
about explored drug targets and new drug targets are being generated. An 
automated literature information extraction system, if available, is desired with this 
consideration. However, biological literature are unstructured materials, which are 
considered very difficult for automated information extraction [170-172]. A survey of 
current literature information extraction technology showed that there are some 
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major obstacles in this application besides those inherited from natural language 
processing. First, the molecule names are difficult to recognize [173]. They are often 
composed of several words that also have their own meanings respectively. This 
makes it difficult to determine the boundary of protein names. Also, various 
abbreviations are used for proteins and nucleotides. The same abbreviation may or 
may not mean the same thing in different contexts. Previous successful attempts in 
automated biomedical literature information retrieval usually work in small domains 
and use name dictionaries to avoid the problem of recognizing protein and nucleic 
acid names [174]. This is not a feasible solution to our application as the work 
needed to construct a complete name dictionary of human proteins and nucleic acids 
is too heavy to be afforded. Second, pronouns are extensively used when describing 
complex relationships between molecules. The determination of the objects 
indicated becomes particularly difficult especially when there are more than one 
pronouns in the same sentence [175]. The third difficulty lies in the understanding of 
generalized terms and narrowed terms. For example, rhodopsin is a kind of 
G-Protein Coupled Receptor (GPCR). The description of the common characteristics 
of all GPCRs will also apply to rhodopsin. To address this problem, it needs the 
biological domain knowledge to be “hard-coded” into the information extraction 
system [176,177], which is an extremely difficult work. Therefore, fully automated 
literature information extraction methods may not be ready for this application until 
the above mentioned problems are sufficiently addressed. However, simple 
automated text retrieval programs based on key word searching are developed to 
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facilitate our search for therapeutic target information, which are proved to be helpful 
in reducing the burden of data collators. 
 With the help of a few automated text retrieval programs developed in PERL, we 
downloaded all the literature in NCBI that contains the phrase “therapeutic target” in 
their abstracts. Efforts have been made to manually extract information from 
available literature. Only those proteins and nucleic acids that had already been 
explored by current therapies or had been suggested explicitly by the author as 
potential therapeutic targets were included in the database. A total number of 433 
targets were found in the literature. It has been reported that approximately 500 
therapeutic targets have been exploited in the currently available medical treatments 
[89]. The search for therapeutic targets aims to collect as many known targets as 
possible. However, descriptions of some of the targets in the literature were not 
specific enough to point to any particular protein or nucleic acid as the targets. 
Hence these targets were not included in this database. 
   
2.3 Therapeutic target database development 
Before undertaking a discussion of therapeutic target database development, it 
is important to determine the expected system functionalities and guidelines for 
further designing processes. The technology platform and software tools suitable for 
this project shall be selected accordingly.  
2.3.1 Requirement analysis 
The database system is expected to store and manage the information about 
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known therapeutic targets. The interested types of information have been discussed 
in the previous section. In consideration of the fast enriching data about known drug 
targets or potential drug targets, a convenient updating mechanism is needed for this 
database. Also, a good system should not be designed to satisfy only the current 
needs; it should also take full consideration of the possible change and extension in 
future. Rational drug design is pacing fast nowadays. Different designing 
approaches take interests in different facets of drug targets. In the foreseeable future, 
more types of information will be needed by new or improved rational drug design 
approaches and therefore needed to be added into this database. Small changes or 
a complete overhaul of the database structure may be needed with this regard. No 
database or other software can be suitable for use forever; however, a flexible 
database structure that can be extended to incorporate these new interests with 
minimum necessary changes is desired. Moreover, the data collection work of two 
other drug mechanism information databases was in progress parallel to the 
development of TTD. As an augmented goal, it would be better that the design and 
implementation codes of TTD can be re-used in the development of these two 
databases. 
Before the actual database development, it is also to be determined which 
technology platform and software tool are to be used to establish this database.  
2.3.1.1 Databases development approaches 
There are several approaches to establish a database in past bioinformatics 
practices. The common ones include the flat-file approach, the relational approach, 
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and the manual approach. 
In the flat-file approach, data is organized in text files where individual records of 
data are represented by a set of lines in strict order with symbols that allow the 
computer to find and retrieve specific pieces of information [178,179]. SWISS-PROT, 
EMBL, GenBank and OMIM are examples of the databases using this approach. 
In the relational approach, a set of tables (also known as relations) are created 
by a database developer to reflect the inter-relationship between the data stored in 
the database [180-185]. Typically database management software such as SQL 
Server, Access, IBM DB2, or Oracle is used to manage the querying, updating and 
re-structuring of the database. The relational approach is so far the most widely 
utilized and dominant mainstream approach to data management. 
In the manual approach, the information is manually coded into static web pages. 
Data are organized hierarchically and can be navigated following the hyper-links 
from the portal page. Usually no software helping the search and management of the 
data is used and limited search facility is provided. This approach mainly serves 
databases with very small scale and highly specific scope, such as the protease 
inhibitor database (http://www.yorvic.york.ac.uk/~proteinase/). 
Manual approach is the easiest way to create an information repository without 
the requirements of any specific software. However, its limitations in search facility 
and data maintenance are severe drawbacks for middle and large scale databases. 
The scale of TTD rules out the manual approach as a good choice. 
The flat-file approach comes from the earliest way of exchanging biological 
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information -- distribution of copies of flat-files to researchers. Since then, a large 
number of biological repositories have emerged, and the availability of the Internet 
has made it possible for researchers to access them without having to install and 
manage local copies of the data. Due in parts to the flat-file based origins, many of 
the major present day biological data repositories, e.g. SWISS-PROT, are 
established using flat-file indexing systems. They are mainly efficient searching 
engines built on the concept of indexing. Information retrieval is performed by 
keywords, or by conjunctive or disjunctive combination of a set of keywords. 
Numerous interfaces [186,187] has been built to allow one to search for desired 
information in a collection of heterogeneous databases. 
The advantage of such flat-file based systems is self-explanatory content that is 
optimized for human readability. The incorporation of hyperlinks into such records 
further allows for extensive cross-referencing. However, the flat-file approach is 
relying on mere text-matching indexing. It shows significant drawbacks in 
comparison to the more comprehensive relational approach, which provides a 
number of desired capabilities for complex queries and data maintenance with the 
support of a relational database management system (RDBMS): 
1. Complex query support is limited. Present flat-file based repositories offer 
HTML forms that accept search terms as input. Search engines parse indexes of 
keyword to find matches, and retrieve matching records. A more elaborate search 
form allows the specification of field specific terms and Boolean combination of 
different search terms. It is important to note that, in the majority of cases, queries 
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are limited to the text matching approach. There is no support for complex queries 
with analytical requirements or nested queries such as “what are the targets unique 
to liver?” This kind of comprehensive listing of organ-wise unique targets has the 
potential to minimize drug side effects. In the contemporary relational databases, 
Structured Query Language (SQL) [188,189], an industrial standard, is supported 
almost unanimously, which could be used to construct virtually all kinds query logic in 
order to get comprehensive and specific results. For instance, the above mentioned 




This SQL statement contains nested query which is not supported by indexing 
engines such as the one in SWISS-PROT. 
2. Data maintenance is tedious and difficult. A flat-file indexing system only 
provides the functionality of a search engine with no support for data maintenance. 
For example, when updating the content of a flat file, there is no constraint that can 
be enforced in normal text-editors to check whether reasonable data have been 
entered in the correct format. For example, one might enter “30-Feb-1997” in a text 
editor as a date by mistake. This obvious error could only be identified by a thorough 
check of the data later. However, A RDBMS will refuse to accept this kind of “illegal” 
SELECT DISTINCT [Target Name]  
FROM [Target Table]  
WHERE [Organ] = ‘liver’  
AND [Target Name] NOT IN  
(SELECT DISTINCT [Target Name] FROM [Target Table] 
 WHERE [Organ] <> ‘liver’); 
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data if appropriate constraints have been enforced. This will significantly reduce the 
error rate in data preparation. Also, any updates in the data files will not automatically 
take effect in the flat-file indexing system. It usually requires a re-indexing process to 
make the changes effective. For big repositories like SWISS-PROT and TREMBLE, 
a complete re-indexing would take more than 10 hours. However in RDBMS, efficient 
algorithms are implanted to keep indices up to date on the fly while you are 
modifying the data. 
3. Views cannot be decoupled from underlying data. In other words, records are 
always retrieved in entirety. This will reduce the query performance due to the 
operations wasted in retrieving irrelevant data. In RDBMS, SQL is able to control 
which information is needed by defining appropriate views upon the tables. An 
RDBMS is able to carry out the queries optimally according to the user defined SQL. 
In view of these advantages of the relational approach over the others, it is 
considered to be the best one for the development of TTD 
2.3.1.2 Selection of RDBMS 
The relational approach requires the support of an RDBMS. The RDBMS 
enables users to create and maintain a relational database. They are designed to 
control data redundancy, restrict unauthorized access, provide persistent storage for 
program objects and data structures, permit inference and actions using rules, 
provide multiple user interfaces, represent complex relationships among data, 
enforce integrity constraints, and provide backup and recovery supports [92,190]. 
Although the direct objective is to develop a therapeutic target database, the 
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selection of the RDBMS should take further considerations for the subsequent 
database projects and the data analysis requirements by other projects of our group. 
Specifically, a desired RDBMS should be able not only to support several small 
databases, but also to hold local copies of existing major public biological databases 
and provide integrated analytical query ability. Therefore, a high performance large 
scale RDBMS is needed.  
As illustrated in Figure 2.1 (May 2001 IDC report on 2000 RDBMSs), the market 
share of RDBMSs is: Oracle (Oracle 9i) 46%, IBM DB2 (DB2 UDB 7.2) 24%, 
Microsoft SQL Server (SQL Server 2000) 7% and others 23%. For better 
compatibility with other existing applications, we decided to choose a RDBMS from 




The factors affecting the selection of RDBMS include: platform and system 









Market Shares of Major RDBMSs
 
Figure 2.1:  Market shares of major RDBMSs. Based on May 2001, IDC report on 
2000 RDBMSs 
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development features, manageability features, security features, analysis ability, 
internet ability, price and performance.  
After a careful technical assessment of the major RDBMSs, Oracle 9i is selected. 
It is clear that SQL Server 2000 was the least expensive of the three. However, it 
could only run on the Windows platform, which limited its performance. DB2 UDB 7 
had just moved from its main frame to Client/Server based database market. Similar 
to Oracle 9i, it could run on many operating systems, and its data types were best 
compatible with ANSI (American National Standards Institute) SQL definitions. 
However, Oracle 9i had the most variety of modules and development tools, 
including modules for data mining and online analytical process, which is essential 
for high-end data analysis purposes. For many years, it had led the way in indexing 
and query optimization technologies while it is not worse than its competitors in other 
important aspects. Also, Oracle 9i is a fully object-oriented database, which 
conforms to the trend toward Object Oriented Programming (OOP). Oracle had kept 
the biggest market share for years. According to the 2001 statistics, over half of the 
fortune 100 corporations used Oracle as their database servers. And finally, it was 
said that the price for a full featured Oracle RDBMS was comparable to that of a full 
featured DB2 RDBMS. Therefore, Oracle 9i was selected to be the platform for our 
database projects and other data analysis tasks. 
After the determination of approach and software platform, the actual database 
design begins. 
2.3.2 Database design 
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The database designing process can and should be divided into three phases: 
conceptual design, logical structure design and physical design, as given in the 
widely accepted Information Engineering Methodology (IEM) [191,192]. The 
conceptual design phase consists of defining the types of information to be stored in 
the database and documenting them. The logical design phase consists of putting 
the conceptual design into practice in the software of choice by creating data tables 
and the relationships between them. Physical design phase allows the designer to 
determine how the data is to be stored on the magnetic media of a computer.  
2.3.2.1 Conceptual design 
The conceptual design phase is a “high-level” phase of design and is 
independent of the choice of database management systems. The result of this 
designing phase is a set of documentation diagrams, whose purpose is to create 
discussion and understanding of the database design before the implementation 
work begins.  
The design documentation that depicts the semantic relationship between data 
is called the entity relationships diagram (ERD) [193,194]. This data modeling 
technique breaks data types down into entity types, attributes and relationship types. 
An entity type is a collection of entities that share common properties or 
characteristics. The properties or characteristics of an entity type or relationship type 
that are of interest to the organization are called attributes. Relationship types are 
meaningful associations between / among entity types. There are three categories of 
relationship types: one-one relationships, one-many relationships and many-many 
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relationships. 
A natural way of drawing the entity relationship diagram is to take target 
molecules, drugs, ligands, and references as entity types and their respective 
properties as their attributes while relationships are established accordingly. For 
instance, the entity type target molecule will have attributes including a unique ID, 
synonyms, cross references, related diseases, functions, pathways involved. And 
they are linked to natural ligands and different types of their drugs by many-many 
relationships. However, this simple method is not applicable because it may result in 
potential multiple-valued attributes which violates the first norm in database design 
and will cause problem in query and data maintenance [195,196]. For instance, the 
attribute “synonyms” may have multiple values for one target. It would be hard for 
applications and SQL queries to distinguish different synonyms within the same data 
item. To address this problem, these “attributes” that might have multiple values are 
“promoted” to weak entity types. A weak entity is an entity of which its existence 
depends on the relation with another entity (the identifying entity). For example, the 
identifying entity type for a weak entity of “target synonym” is an entity of “target 
molecule”. The existence of “target synonyms” depends on their relationship to a 
“target molecule”. A weak entity has no key attribute because it cannot exist without 
the relation it has to its identifying entity. The resulted first draft of ERD (using 
"Crow's Foot" notation, which is the accepted IEM convention) is shown in Figure 2.2. 
To have a clearer view of the attributes of relationships, in this ERD, any relationship 
with attributes is drawn as weak entities identified by both sides of the relationship.  
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2.3.2.2 Logical design 
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In the logical structure design phase, the structure of the database (also known 
as database schema) is created, which is a set of data tables and their connections. 
The data tables and the connections between them can be directly derived from the 
ERD. However, this approach does not, by itself, assure a good relational database 
for every purpose. The first design of TTD schema was derived from the above ERD, 
which was evaluated on a small set of sample data and disclosed several problems 
about this design. Accordingly, a series of modifications on the first schema is carried 
to introduce more unification on the data representation and flexibility to 
accommodate extensions. The latest revised schema resembles a semantic network 
in ontology research very much. These designing processes are detailed as follows. 
2.3.2.2.1 ERD derived database structure 
The algorithm for translating a sound conceptual design into a relational data 
structure is given in [197,198] as the following four steps: 
First, construct a table for each entity type, containing all the attributes of the 
entity type and having a primary key or a unique identifier filed. 
Second, construct a table for each many-many relationship type containing the 
unique identifier for each side of the relationship along with the attributes of the 
relationship. 
Third, for each one-many relationship type, add the unique identifier from the 
“one” side to the table corresponding to the entity on the “many” side, along with all 
the attributes of the relationship. 
Finally, for each one-one relationship type, add the unique identifier from either 
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side to the table for the other side, along with the attributes of the relationship. 
Using this algorithm, an initial version of therapeutic target database can be 
constructed, which consists of sixteen tables, as shown in Table 2.1. One table is 
created for the target molecule entity type, which includes two columns -- the unique 
identifier assigned to each target and its recommended name. Those types of 
information with one-many relationships to a target, such as synonyms, related 
diseases / conditions, functions, pathways involved, are stored in their respective 
tables with the unique identifiers of their identifying targets. The many-many 
relationship between target molecules and their different types of drugs are stored in 
one table, which contains the unique identifiers of targets, the unique identifiers of 
drugs that bind the targets, and the types of the drugs. The many-many relationship 
between target molecules and their natural ligands are also stored in one table 
structurally similar to the table of target-drug relationship. To provide the information 
sources for data quality assessments, the tables storing information collected from 
literature, such as the tables for target functions, target pathways, different types of 
drugs and ligands, all contain one column storing the unique identifier of 
corresponding references. For each drug, a unique identifier was assigned and it 
was stored in one table with the recommended name of that drug, its molecular 
weight and its molecular formula. Those types of information with one-many 
relationships to a drug, such as drug synonyms, CAS RN, and chemical 
classification, are stored in their respective tables with the unique identifier of their 
corresponding drugs. In this design, CAS RN is treated as an entity type with 
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one-many relationship to a drug, which is different from most of the current available 
chemical databases, such as ACX and the Merck index, which usually provide only 
one CAS RN for each chemical. This is because while in most of the cases, a 
chemical only has one CAS RN and vice versa, a small number of exceptions do 
exist. For example, GTP (guanosine triphosphate) has two CAS RNs: 86-01-1 and 
56001-37-7. Drug and natural ligands are all small chemicals that have the same 
types of information. Therefore, the data tables created for natural ligands are similar 
to those for drugs. The table storing information about references is relatively simple. 
It only contains two columns of unique identifier and reference citation. 
 
Table 2.1: The data tables created in the first design of TTD.  
 
Table Name Columns Table Relationships 
TTDTG: 
Drug targets  
TID: Target unique identifier 




DID: Drug unique identifier 
NM: Recommended drug name 
MW: Molecular weight 




LID: Natural Ligand unique identifier 
NM: Recommended ligand name 
MW: Molecular weight 




RFID: Reference unique identifier 
RF: Reference citation 
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TTDTS 
Target synonyms 
TID: Target unique identifier 
SN: Target synonym 




TID: Target unique identifier 
PW: Pathway name 
RF: Reference unique identifier 
TID ∈  TTDTG.TID 




TID: Target unique identifier 
DN: Disease name 
RF: Reference unique identifier 
TID ∈  TTDTG.TID 
RF ∈  TTDRF.RFID 
TTDTF: 
Target functions 
TID: Target unique identifier 
FN: Target function 
RF: Reference unique identifier 
TID ∈  TTDTG.TID 
RF ∈  TTDRF.RFID 
TTDTDG: 
Drugs that bind 
targets 
TID: Target unique identifier 
DG: Drug ID 
TP: Drug category 
RF: Reference unique identifier 
TID ∈  TTDTG.TID 
RF ∈  TTDRF.RFID 
DG ∈  TTDDG.DID 
TTDTLG: 
Natural ligands that 
bind targets 
TID: Target unique identifier 
LG: Natural ligand ID 
RF: Reference unique identifier 
TID ∈  TTDTG.TID 
RF ∈  TTDRF.RFID 
LG ∈  TTDLG.LID 
TTDDS: 
Drug synonyms 
DID: Drug unique identifier 
SN: Drug synonym 
DID ∈  TTDDG.DID 
TTDDR: 
Drug CAS RN 
DID: Drug unique identifier 
CAS: CAS Registration Number 




DID: Drug unique identifier 
DC: Drug classification 
DID ∈  TTDDG.DID 
TTDLS: 
Ligands synonyms 
LID: Natural ligand unique identifier 
SN: Natural ligand synonym 
LID ∈  TTDLG.LID 
TTDLR: 
Ligand CAS RN 
LID: Natural ligand unique identifier 
CAS: CAS Registration Number 
LID ∈  TTDLG.LID 




LID: Natural ligand unique identifier 
LC: Natural ligand classification 
LID ∈  TTDLG.LID 
 
After the tables and their relationship (constraints) were created, a web interface 
of the database was sketchily implemented and the system was analyzed on a small 
set of testing data. The above data structures showed several weaknesses in the 
test run. They can be summarized as below: 
First, the information retrieval of a single target involves many tables. It is not a 
big issue when the tables are queried or analyzed by SQL statements. However, 
when building the web interface for the database, each table needs a distinct record 
set object in the web server, which will lead to inefficient use of web server resources. 
Also, the big number of objects requires a corresponding size of codes to manipulate 
them, which makes the debug and maintenance of these codes troublesome. 
Second, the interface codes developed on this structure are fairly rigid to 
accommodate extension of the database. For example, in the later designing stages, 
it was suggested that it would be better to classify the therapeutic targets into 
different categories according to its related diseases / conditions, in order to facilitate 
systematical studies. Accordingly, the classification information for therapeutic 
targets should be added into the database. With the rapid progress in rational drug 
design approaches, it is foreseeable that more types of information will be needed by 
novel or improved methods. The ability to accommodate these extensions with 
minimal changes in the database structure and all its application codes is desired. In 
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this design, in order to incorporate the classification information, a new table storing 
the unique identifier of targets and their classes needed to be added into the 
database. Big changes on the interfacing codes were required to use the new table. 
Actually, not only the web interface but also all the database applications written in 
programming languages requiring extensive coding (such as C/C++) will suffer from 
this problem. The expandability and life cycle of this database are therefore 
considerably compromised. Also the database structure and interface codes, 
developed in this manner, are unable to be re-used in the development of other 
databases. 
2.3.2.2.2 Revised database structure 
A careful analysis of the first design revealed possible directions to address the 
above problems. First, in the above data structure, most of the tables were quite 
similar in terms of the data types stored in them. Many of them consisted of three 
columns: a column for the unique identifier of an entity type (target, drug or ligand), a 
column for a property of the entity type (i.e. natural ligands of targets or synonyms of 
drugs) and a column for the corresponding unique identifier of a reference citation. 
This similarity provides the possibility of reducing the number of tables by merging 
similar ones. Second, in order to minimize the effort needed when new types of 
information were to be added into the database, the applications shall be able to 
“notice” the changes in the database and adapt to the changes automatically. One 
possible solution would be providing the “database structure” information in one of 
the tables.  
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The above considerations led to the revised ERD shown in Figure 2.3. Each kind 
of relationship type, regardless of its type (one-one, one-many or many-many), are 
given a unique identifier. The unique identifiers of different relationships and their 
descriptions are stored in one table so that applications will be able to access the 
types of relationships stored in the database. The relationships are divided into two 
categories. One category of relationships links an entity to its attributes, regardless 
of single-valued attributes or multi-valued attributes. The other category of 
relationships links two entities together, where the other entity is represented by its 
unique identifier. All the information in this database can therefore be represented in 
a quadruple notation and stored uniformly. The quadruple notation includes the 
unique identifier of an entity, the unique identifier of a relationship, the right hand side 
of the relationship (either a property value or a unique identifier of another entity, 
according to the relationship category) and the unique identifier of the reference 
where this piece of information comes from. For example, “prostaglandin H2 
synthase is a therapeutic target for treating inflammation” will be stored in the 
database in the quadruple form: 
 (“TTT0000600”, “D105”, “Inflammation”, “10878289”) 
where “TTT0000600” is the unique identifier for the target prostaglandin H2 synthase; 
“D105” is the unique identifier for the relationship between targets and their related 
diseases; “10878289” is the unique identifier of the reference where this information 
is extracted. Similarly, “prostaglandin H2 synthase has an inhibitor, aspirin” will be 
stored in the database in the quadruple form: 
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(“TTT0000600”, “D141”, “TTD0000354”, “8728890”) 
where “D141” is the unique identifier for the relationship between targets and 
their inhibitors, “TTD0000354” is the unique identifier of the drug aspirin and 
“8728890” is the unique identifier of the reference where this information is extracted. 
In this revised schema, there are only three tables and applications can access the 
“logical structure” of the database by reading the information in the relationships 
table. Also, to support the continuous work of data maintenance, a housekeeping 
field storing the latest update time of each piece of information is added. This revised 
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Figure 2.3: Revised Entity Relationship Digram of TTD.
 
Table 2.2: The data tables created in the revised design of TTD. 
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Table Name Columns Table Relationships 
TTDINFO: 
Information 
ID: Unique identifier of an entity 
TP: Unique identifier of a relationship 
CT: Property value 
RF: Unique identifier of the reference 
UPD: Latest update time 
TP ∈  TTDTP.TP 
RF ∈  TTDRF.RFID 
TTDRF: 
References 
RFID: Reference unique identifier 




TP: Unique identifier of a relationship 
NM: Relationship name 
MD: Relationship category. 
 
 
2.3.2.2.3 Further analysis of the revised database structure 
This quadruple notation is applicable not only to this database but also to the 
other drug mechanism databases that were developed in parallel, which enabled the 
reuse of the TTD database schema and interface codes in the development of these 
databases. This universal applicability of this schema may be partly explained by its 
resemblance to semantic networks that are used in ontology research. 
Ontologies are frameworks developed principally by the AI (Artificial Intelligence) 
community in the 1970s and 1980s to represent the key concepts in any research 
field and their inter-relationships [199]. Many bioinformatics specialists believe that 
they are necessary not only to make database annotations accessible to analysis 
tools, but also to facilitate information retrieval. For example, searching for all 
G-protein-coupled receptors in a database would be easier with software that 
“knows” that these proteins might be variously annotated as “transmembrane 
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protein”, “7TM protein”, “GPCR” or “opsin”.  In the 1960s and 1970s, the artificial 
intelligence (AI) community developed several systems to embody this sort of 
complexity. One such system, the semantic networks, represents concepts as nodes 
in a graph, which are joined by arcs that specify their relationships [200-202]. 
Semantic network is the approach taken by many bioinformatics ontologies. It is 
hoped that by building these lattices of semantic associations and by hooking 
database entries to the appropriate points, ontologies can be used to resolve the 
problem of database integration.  
GPCR
Opsin G-protein CoupledReceptorIs a kind of
Euqal toIs a kind of
Figure 2.4: An example of semantic networks.
 
When a semantic network notation is devised, it is necessary to specify not only 
the types of the node and arcs, as well as the ways they can be combined, but also 
their meanings. In the above example, there are three issues. First, synonyms are 
used to describe the same entity (for example, “GPCR” and “G-protein-coupled 
receptor”). Second, relationships are required to group related concepts together (for 
example, “opsin” is a kind of “GPCR”). Third, there are subtle differences between 
terms (for example, “transmembrane” describes the location of a protein that might 
or might not be a GPCR). Unless the meanings of the relationships are specified 
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precisely, the semantic network is meaningless [203]. An example of a semantic 
network is shown in Figure 2.4. 
The revised data structure could be regarded as an extended semantic network. 
In this sense, the quadruple notation could be interpreted as if two nodes were linked 
by an arc with the reference. The exact meanings of the arcs (relationships) are 
stored in the relationships table. Ontologies are built for the integration of databases. 
Therefore, this ontology-like data structure is also expected to enable easy 
integration with other databases and maximizes the re-usability of the application 
codes developed on this data structure.  
Normalization is also a very important issue in database design [195,198]. The 
following normal forms (NFs) have been defined: 1NF, 2NF, 3NF, BCNF, 4NF, and 
PJ/NF(5NF) [204]. Normalization theory is simply a formalization of the “one fact in 
one place” principle of good design. If a database schema satisfies a specific set of 
rules, it is said to be in some normal form. Normal forms are thus specific sets of 
rules. Each higher normal form includes all the rules of all lower normal forms. For 
example, a table in the third normal form satisfies all requirements for 1NF, 2NF and 
3NF. The normal form requirements up to 3NF are listed below: 
1NF: This normal form specified the granularities of data. It requires no relations 
within attributes, no composite attributes, no multi-valued attributes and no nested 
relations. 
2NF: In this normal form, all the requirements of 1NF shall be satisfied besides 
every non-prime attribute is fully functionally dependent on the key. 
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3NF: In this normal form, all the requirements of 2NF shall be satisfied besides 
no non-prime attribute can be determined by another non-prime attribute. 
Normalization may be an abused principle. Excessive normalization will lead to 
a poor performance of the database. Thus normalization should be carried out 
cautiously [204]. In general, the third normal form (3NF) is regarded sufficient for 
therapeutic target database and the revised schema conforms to the third normal 
form. 
One problem that the revised data structure might face is that the referential 
integrity could no longer be enforced by simply adding foreign key constraints on 
relevant columns. However, this problem could be solved by setting up triggers to 
check the referential integrity in Oracle 9i. 
The revised schema and the first ERD derived schema are mutually convertible. 
In a sense, the revised data structure could be viewed as each table in the first 
schema was attached by a tag of its identity and stored together. To convert data 
from the revised schema to the first ERD derived schema, one only needs to group 
the records according to their relationship type column (TP) and store different 
groups of records in different tables. To convert data from the first ERD derived 
schema to the revised schema, one just needs to add the relationship type 
information into the each table and then store them centrally. During the 
development of the database, a script was written to do these conversions 
automatically when needed. 
2.3.2.3 Physical design 
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After the data structure was fixed, how the data would be stored on the magnetic 
media of the computer needed to be determined. As most of the modern database 
management systems, Oracle 9i can take care of this problem for the user. This 
designing phase is mentioned here as a distinct section only for the sake of 
completeness. 
After all the above designing activities, the database can be then implemented 
and the maintenance work will keep on going all across the life cycle of the 
database. 
2.3.3 Implementation 
There are two parts of work needed to be done to establish a publicly accessible 
database. One is on the RDBMS side and the other is on the web interface side. 
According to the above revised design, tables were set up in the RDBMS and 
the referential integrity was enforced by setting up triggers. A package was created 
to collect all the PL/SQL programs written for this database, including scripts to load 
data, check referential integrity, convert data formats, do housekeeping work as well 
as support the functionalities of the web interface [92,190]. 
Various technologies can be used to build the web interface which creates 
dynamic web presentations according to a viewer’s interest. Common techniques 
include JSP (Java Server Pages) [205], PHP (Personal Home Page) [206], ASP 
[207], and Perl (Practical Extraction and Reporting Language) DBI (DataBase 
Interface) [208] based applications. Among them, ASP has a big advantage on its 
ease of use. It supports ADO (ActiveX Data Objects) objects [209], ODBC (Open 
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DataBase Connectivity) [210] and OLE-DB (Object Linking and Embedding 
DataBase) [211] which make the development of web interface for databases much 
easier. Although in terms of run-time resource usage, ASP is not as good as JSP, it is 
still better than traditional CGI (Common Gateway Interface) [212] based 
approaches such as Perl DBI based applications. It is said that ASP technology is 
very good for middle-range applications, which fits TTD very well. 
Using the ASP technology, the interface of TTD was developed, which has a 
URL at http://xin.cz3.nus.edu.sg/Group/ttd/ttd.asp. The portal page is shown in 
Figure 2.5. TTD is searchable by target name or drug/ligand name. It can also be 
accessed by selection of disease name, drug/ligand function, or drug therapeutic 
classification from the list provided in the corresponding selection field. Searches 
involving any combination of these five search or selection fields are also supported. 
Each search or selection field in this page will match one or more types of 
information in the database. For example, if any of the “recommended name” or 
“synonyms” of a target matches the term specified in the “target name” filed, this 
target is considered a hit. 
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The search is case insensitive. In a query, a user can specify full name or any 
part of the name in a text field, or choose one item from a selection field. Wild 
characters of “*” and “?” are supported in the text field. “?” represents any one 
character and “*” represents a string of characters of any length. For example, input 
of “phosphatase” in the target name field finds entries containing “phosphatase” in 
their name, such as Cdc25A phosphatase or tyrosine phosphatase.  On the other 
hand, input of “Cdc25? phosphatase” finds entries with names like Cdc25A 
phosphatase, Cdc25B phosphatase and Cdc25C phosphatase.  Likewise, input of 
“Cdc* phosphatase” finds the same entries as above. In this case, “*” represents 
“25A”, “25B” or “25C”. “*” and “?” are not the wild characters used in SQL, therefore, 
all the terms are pre-processed so that they can be correctly interpreted. 
The query conditions are persevered throughout a query session by cookies. 
The result of a typical search is illustrated in Figure 2.6. SQL query statements were 
Figure 2.5: The portal page of TTD web interface 
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dynamically constructed to pick out the summary information of the targets satisfying 
the criteria specified in the first page. In this page, all the therapeutic targets found 
are listed along with the disease conditions to be treated, drugs or ligands that bind 
the target, and its classification. This summary information is generated 
automatically by a PL/SQL scripts with parameters specifying which types of 
information shall be included. ASP codes for this page were written in a manner that 
they are able to automatically adapt to different types of summary information. 
Detailed information of a target can be obtained by clicking the corresponding target 
name. 
The interface displaying the detailed information of a target is shown in Figure 
2.7. ASP codes for the generation of this page read the relationships type table 
TTDTP in the database and display all types of information about the target currently 
available. From the page shown, one finds target name, corresponding disease 
condition and cross-link to Karolinska disease database (http://www.kib.ki.se/), target 
function,  pathway, corresponding natural ligand, known drugs or ligands directed at 
the target, drug type (such as inhibitor, antagonist, and blocker etc.), drug 
therapeutic classification, and additional cross-links to other databases that provide 
useful information about the target.  
 




Figure 2.7: The TTD web interface of the detailed information of a target 
Figure 2.6: The TTD web interface of a search result 
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2.4 Preliminary analysis of TTD 
A total number of 433 protein and nucleic acid targets were collected in TTD. As 
shown in Figure 2.8, two major classes of molecules contribute to more then three 
quarters of the total therapeutic targets, which are enzymes (44%) and receptors 
(33%). Other significant classes of therapeutic targets include hormones and factors 
(10%), ion channels (4%) and nucleotides (3%). This composition is generally in 
agreement with that reported in 1997[213]. These targets cover 125 different 
diseases / conditions, and 809 distinct drugs / ligands directed at these targets are 
collected in this database. 
 
 
2.5 Extension of the TTD database schema and interface 
The information on drug adverse reaction and drug Absorption Distribution 
Figure 2.8: Biochemical classes of drug targets in TTD 
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Metabolism and Excretion (ADME) associated proteins are collected in parallel to the 
development of TTD. These are also very important aspects that affect the success 
of a drug.  
While developing the database schema and web interface for the therapeutic 
target database, attentions have been paid to develop re-usable modules. By 
reading the relationship table, the ontology like database schema of TTD and its 
interface codes can virtually adapt to any predefined sets of information types, 
including those needed by drug adverse reaction information and drug ADME 
associated proteins information. Therefore, the work of TTD is readily extendable to 
the development of these two drug mechanism databases, namely the Drug Adverse 
Reaction Database (DART) [214] and drug ADME associated protein database 
(ADME-AP) [215]. 
Drug adverse reaction is often induced by the interaction of a drug or its 
metabolites with specific protein targets related to toxicity or side effects 
[117,216-219]. Knowledge about these targets is both important in facilitating the 
study of the mechanism of drug adverse reaction and in new drug discovery. It is 
also useful in the development and testing of rational drug design and safety 
evaluation tools [220-223]. The Drug Adverse Reaction Database (DART) is 
intended to provide comprehensive information about toxicity and side effect targets 
to the relevant communities. DART contains information about known toxicity and 
side effect related proteins described in the literature together with physiological 
function of each target, related diseases, corresponding agonists / antagonists / 
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activators / inhibitors, IC50 values of the inhibitors, and the toxic effect or side effect 
resulting from the binding of a drug. Cross-links to other databases are also 
introduced to facilitate the access of information about the sequence, 3D structure, 
function, and nomenclature of each target along with drug/ligand binding properties, 
and related literature. Each entry can be retrieved through multiple methods 
including target name, target physiological function, toxicity or side effect, ligand 
name, and biological pathways. This database can be accessed at 
http://xin.cz3.nus.edu.sg/group/dart/dart.asp. 
Drug absorption, distribution, metabolism and excretion are the processes prior 
to and after drug-target interaction. It often involves interaction of a drug with specific 
proteins [224-229]. Knowledge about these ADME-related protein targets is 
important in facilitating the study of the mechanism of drug transportation, disposition 
as well as therapeutic action. It is also useful in the development and testing of 
rational drug design and pharmacokinetics prediction tools [225,230-235]. The 
ADME associated protein database ADME-AP is intended to provide information 
about proteins acting as ADME targets described in the literature. This database 
gives description about physiological function of each target, membrane location and 
tissue distribution, transport direction, driving force, substrates that bind to a target, 
pharmacokinetic effect in terms of ADME classification, synonyms and gene name. 
Cross-links to other databases are also provided to facilitate the access of 
information about the sequence, 3D structure, function, genetic disorder and 
nomenclature of each target along with drug/ligand binding properties, and related 
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literature. Each entry can be retrieved through multiple methods including target 
name, ADME class, ligand/substrate name, and target physiological function. This 
database can be accessed at http://xin.cz3.nus.edu.sg/group/admet/admet.asp. 
 
2.6 Summary 
Therapeutic target database is developed from information in available literature, 
which is a result of collective and persistent effort over the years. It integrates the 
general information of therapeutic targets such as physiological functions and their 
therapeutic related aspects. With the rapid development of proteomics [95,236] and 
pathway analysis [237], the relevant information can be incorporated or the 
corresponding databases can be cross-linked to TTD to provide more 
comprehensive information about the drug targets and their relationship to other 
biomolecules and cellular processes.  
An ontology-like database schema is designed for TTD which can easily 
incorporate new interests in therapeutic targets. Interface codes developed on this 
schema are also highly flexible. The work in TTD has been extended to develop two 
other drug mechanism information databases – DART and ADME-AP. 
The completion of TTD not only provides a convenient way of looking up 
therapeutic target information, but also brings new research opportunities, such as 
the study of novel approaches in discovery of new therapeutic targets and new 
therapeutic intervention strategies, which are discussed next. 






Prediction of Drug-target like proteins  
 
In this chapter, we explore the use of statistical learning approaches to predict 
drug-target like proteins from their primary sequences in order to facilitate the rapid 
discovery of new potential therapeutic targets from the large quantity of sequences in 
human genome. A number of statistical learning methods and pre-processing 
techniques are explored. It was found that the Support Vector Machine (SVM) 
algorithm with a fine-tuned Gaussian kernel was able to make reasonably accurate 
prediction, which showed its potential to be used in the genome scale rapid drug 




Target discovery constitutes one of the main components of today’s early stage 
pharmaceutical research [3,74]. The aim of target discovery is to identify and validate 
suitable drug targets (i.e. proteins or nucleotides to which drug binding produces 
therapeutic effects) for therapeutic interventions. Only a small fraction of proteins are 
actually targeted by today’s drugs. Indeed, a review article published in 2000 
estimated that current therapies explored less than 500 distinct targets [89]. The total 
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number of tractable targets remains difficult to estimate given the uncertainty 
surrounding the total number of human genes. However, it has been estimated that 
the number of drug targets is probably in the range of 5,000-10,000 [89]. This 
number is 10-20 times greater than that of the currently explored drug targets. 
The discovery of targets that are sufficiently robust to yield marketable 
therapeutics is an enormous challenge. Through the years, many approaches have 
been used with varying degrees of success. Most of them are disease dependent 
[95], for example, target-independent screening of tumor-derived cell lines, 
reductionist approaches to identifying crucial elements in disease-affected pathways, 
“global” examination of gene transcript levels, and global examination of protein 
expression levels. These are mainly wet-lab based approaches which require the 
consumption of large amount of money and time. Disease-independent approaches 
were also reported, such as screening of homologs of previously drugged targets.  
The fruits of the Human Genome Project will undoubtedly change how and 
where we look for new drugs and how we assess drug targets [238,239]. With the 
exception of these infectious disease targets, which are proteins or nucleotides 
essential to viral replication or bacterial metabolism in the infectious organisms, most 
of the drug targets are human proteins. Many more targets responsible for 
debilitating human diseases are waiting to be uncovered from the large number of 
genes composing the human genome. It is expected that the search engines and 
powerful analytical techniques developed in bioinformatics and rational drug design 
may help a lot in future target discovery. Rapid genome scale in silico 
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disease-independent target discovery methods are desired in this endeavor. 
Drug targets are a unique group of proteins bearing certain common 
characteristics. For example, a good target must possess substantial regulatory 
effect on a pathogenic pathway and the effect should be limited to that pathway so 
that normal processes of human body will not be disturbed. Therefore not 
surprisingly, a big portion of explored targets are receptors whose functions are 
highly important and specific to certain pathways. According to 2000 statistics, these 
receptors contribute to 45% of all current targets. Also, enzymes, whose activities 
are usually highly specific, make up for 28% targets [89]. It is easy to see that some 
protein classes are, obviously, more “successful” or exhibit better tractability in the 
drug discovery process. This shows that the drug-target likeness of a protein is 
related to its classes of structure and function, which are ultimately determined by its 
sequence. Statistical learning approaches have been applied to find the relationship 
between protein sequences and their functions [240-244], which lead to the 
hypothesis that the statistical learning methods may be equally applicable in 
prediction of drug-target like proteins, which is an efficient approach to pick out 
candidate targets from the huge number of proteins in the human genome. 
The establishment of therapeutic target database has provided a useful resource 
for statistical model training. Various statistical approaches are evaluated in this work 
to examine whether statistical learning approaches can show satisfactory capacity in 
recognizing novel potential therapeutic targets by analysis of the sequences of 
explored therapeutic targets. 




3.2 Statistical learning 
With regard to this application, a supervised binary classification method is 
needed [245]. Specifically, examples are represented by a vector of a fixed number 
of attributes (denoted by NAAA ..., 21 ), also known as features, describing different 
characteristics of the examples. A given set of class labels (denoted by C ), for 
example }1,1{ −+  in binary classification, labels all the examples, where the 
examples labeled “+1” are called positive examples, and the examples labeled “-1” 
are called negative examples. Supervised learning methods, also known as 
classification methods, are to build a set of models that can correctly predict the 
class labels of a set of different examples (testing examples) based on the 
knowledge represented by a set of examples with known class labels (training 
examples). 
3.2.1 Classification algorithms 
 Over the years, a variety of different classification algorithms have been 
developed by the machine learning community. Examples of such algorithms are 
decision tree bases [246-248], rule-based [249,250], probabilistic [251], neural 
network [252,253], genetic [254], instance based [255,256], and support vector 
machine [104,245]. Depending on the characteristics of the data sets being 
classified, certain algorithms tend to perform better than others. In recent years, 
algorithms based on the support vector machine and the k-nearest neighbors have 
been shown to produce reasonably good results for problems in which features are 
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continuous. For this reason, we are mainly interested in these two algorithms. We 
also include the decision tree algorithm, which is the “classical” benchmark for 
classification algorithms and can be applied universally. These algorithms are 
described briefly below. 
3.2.1.1 Decision tree 
 Decision trees are powerful and popular tools for classification and prediction 
[246-248]. The attractiveness of decision trees is due to the fact that, in contrast to 
neural networks and support vector machines, decision trees represent rules. Rules 
can readily be expressed so that human can understand them. They can even be 
directly used in a database access language like SQL so that records falling into a 
particular category may be retrieved.  
There are a variety of algorithms for building decision trees that share the 
desirable quality of interpretability. A well known and frequently used decision tree 
algorithm over the years is ID3 (or its improved version C4.5 and its commercial 
counterpart See5/C5.0).  
Decision tree is a classifier in the form of a tree structure (Figure 3.1), where 
each node is either a leaf node, which indicates the class labels of examples, or a 
decision node, which specifies some test to be carried out on a single attribute value 
and has one branch and sub-tree for each possible outcome of the test. A decision 
tree can be used to classify an example by starting at the root of the tree and moving 
through it until a leaf node, which provides the class label of the example. 
 




Decision tree induction is a typical inductive approach to learn knowledge on 
classification. Most algorithms that have been developed for learning decision trees 
are variations on a core algorithm that employs a top-down, greedy search through 
the space of possible decision trees. ID3 is a widely used decision tree learning 
algorithm [257]. It uses fixed sets of attributes, and creates a decision tree to classify 
an example into a fixed set of class labels. At every step, if the remaining examples 
are all of the same class, it predicts that class, otherwise, it chooses the attribute with 
the highest “information gain” and creates a decision node based on that attribute to 
split the remaining training examples into one subset per discrete value of that 
attribute. It recursively does this until each leaf node contains only examples of one 
class, or all the attributes are used up.  
The primary focus of the decision tree growing algorithm is to select which 
A1
C= +1 A3C= -1 C= -1
C= -1 C= -1
A1= Red A1=Blue








Figure 3.1: An example of decision trees. 
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attribute to test at each decision node in the tree. The quantitative measure of the 
worth of an attribute used in ID3 is a statistical property called “information gain” that 
measures how well a given attribute separates the training examples according to 
their class labels. 
In order to define information gain precisely, we need to define a measure 
commonly used in information theory, called entropy (denoted by E ), which 
characterizes the impurity of an arbitrary collection of examples. Given a set S , in 
the binary classification setting, the entropy of set S  is defined as: 
nnppSE 22 loglog)( −−=          Equation 3.6 
where p  is the proportion of positive examples in S  and n  is the proportion of 
negative examples in S . In all calculations involving entropy we define 0log0 2  to 
be 0. Notice that the entropy is 0 if all members of S  belong to the same class, 
which is the stop criteria of tree splitting; and the entropy is 1 (at its maximum) when 
the collection contains equal numbers of positive and negative examples. If the 
collection contains unequal numbers of positive and negative examples, the entropy 
is between 0 and 1.  
 One interpretation of entropy from information theory is that it specifies the 
minimum number of bits of information needed to encode the classification of an 
arbitrary member of S  (i.e., a member of S  drawn at random with uniform 
probability) [258]. For example, if p  is 1, a receiver knows the drawn example will 
be positive, so no message need be sent, and the entropy is 0. On the other hand, if 
p  is 0.5, one bit is required to indicate whether the drawn example is positive or 
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negative. If p  is 0.8, then a collection of messages can be encoded using less than 
1 bit (on average) per message by assigning shorter codes to collections of positive 
examples and longer codes to less likely negative examples.  
Given entropy as a measure of the impurity in a collection of training examples, 
we can now define a measure of the effectiveness of an attribute in classifying the 
training data. The measure we will use, called information gain, is simply the 
expected reduction in entropy caused by partitioning the examples according to this 
attribute. More precisely, the information gain ),( iASG  of an attribute iA , relative 













=∑−=        Equation 3.7 
where )( iAV  is the set of all possible discrete values for attribute iA , and vAiS =  is 
the subset of S  in which attribute iA  has the value v . Note the first term in the 
equation of ),( iASG  is just the entropy of the original collection S  and the second 
term is the expected value of the entropy after S  is partitioned using attribute iA . 
The expected entropy described by this second term is simply the sum of the 
entropies of each subset vAiS = , weighted by the fraction of examples S
S vAi =  that 
belong to vAiS = . ),( iASG  is therefore the expected reduction in entropy caused by 
knowing the value of attribute iA . Put another way, ),( iASG  is the information 
provided about the class labels, given the values of some attribute iA . The value of 
),( iASG  is the number of bits saved when encoding the class labels of an arbitrary 
member of S , by knowing the value of attribute iA .  
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 The measure G  tends to favor those attributes with more possible discrete 
values. For example, a decision tree can be established to predict the disease of a 
patient using only one attribute: the case serial number. However, this decision tree 
would probably fail when a new patient with a new case serial number comes. 
Another measurement, Gain Ratio ( R ) is defined to avoid this bias, which can be 
calculated as follows. 














ASIV        Equation 3.9 
where )( iAV  is the set of all possible discrete values for attribute iA ; vAiS =  is the 
subset of S  for which attribute iA  has value v  and the norm of a set ⋅  is 
defined as the number of elements in the set. ),( iASIV  can be interpreted as the 
total information content of the attribute iA . Therefore, Gain ratio is the ratio of 
information gained that is pertinent to classification by branching on iA . 
The initial definition of decision tree is restricted to attributes that take on a 
discrete set of values. In other words, the attributes tested in the decision nodes of 
the tree must also be discretely valued. This restriction can easily be removed so 
that continuous-valued decision attributes can be incorporated into the learned tree 
[259]. This can be accomplished by dynamically defining new discrete-valued 
attributes that partition the continuous attribute value into a discrete set of intervals. 
For instance, for an attribute iA  that is continuous-valued, the ID3 algorithm can 
dynamically create a new Boolean attribute iA'  that is true if cAi <  and false 
otherwise. The only question is how to select the best value for the threshold c . 
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Clearly, we would like to pick a threshold that produces the greatest information gain. 
By sorting the examples according to the continuous attribute iA , then identifying 
adjacent examples that differ in their class labels, we can generate a set of candidate 
thresholds midway between the corresponding values of iA . It can be proven that 
the value of c  that maximizes information gain must always lie at such a boundary. 
These candidate thresholds can then be evaluated by computing the information 
gain associated. This dynamically created Boolean attribute can then compete with 
the other discrete-valued candidate attributes available for growing the decision tree. 
Normally, the process of selecting a new attribute and partitioning the training 
examples is repeated for each non-terminal descendant node, using only the training 
examples associated with that node. This process continues for each new leaf node 
until either of two conditions is met:  
Every attribute has already been included along this path through the tree, or  
The training examples associated with this leaf node all have the same class 
labels (i.e., their entropy is zero).  
In principle, the above decision tree algorithm can be used to grow each branch 
of the tree just deeply enough to perfectly classify the training examples. While this is 
sometimes a reasonable strategy, in many cases it can lead to difficulties when there 
is noise in the data, or when the number of training examples is too small to give a 
representative sample of the reality. In either of these cases, this simple algorithm 
will produce trees that over-fit the training examples. Therefore, after the tree is 
constructed, a pruning process is applied to gradually remove decision nodes that 
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give the least improvements on accuracy and assign to these nodes the class label 
of the majority of remaining examples [260,261]. In this case, the prune level will be 
a free parameter to be optimized in the decision tree induction, which controls the 
complexity of the tree. 
3.2.1.2 K-nearest neighbor 
 K-nearest neighbor (kNN) is a well known and widely used instance-based 
classification algorithm due to its conceptual simplicity, general applicability and 
efficiency [255,262-264]. It can be used as an initial tool to analyze a data set before 
proceeding to more sophisticated methods. It is also used to benchmark results of 
other classification methods. K-nearest neighbor is an algorithm that uses all 
available examples and classifies new instances based on a similarity measure.  
The basic idea behind this classification paradigm is first to compute the 
similarity between a test example and all the examples in the training set, then to 
select the k  most similar training examples, and finally to determine the class label 
of the test example based on the class labels of these k  nearest neighbors. 
One of the advantages of k-nearest neighbor method is that it is well suited for 
composite classes (classes consists of examples whose features have different 
characteristics for different subsets, or sub-classes) as its classification decision is 
based on a small neighborhood of similar examples.  
 Two steps are critical to the performance of the k-nearest neighbor. The first is 
the method used to determine the similarity between a test example and the 
examples in the training set and the second is the method used to determine the 
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class label of the test example based on the class labels of the nearest neighbors. 
For data sets for which the objects are represented by multi-dimensional vectors, like 
our application, the approach that is commonly used to compute the similarity is 
using the Euclidean distance or any other norm based distance. We use the 
Euclidean distance as the similarity measurement in our experiments.  
 The other step to determine the class of the test example based on the classes 
of its k-nearest neighbors is to assign it to the majority class, i.e., the class to which 










)(            Equation 3.10 
where )( iVc  is the class label of the i -th nearest neighbor iV . 
 In the k-nearest neighbor classification, the value of k  is needed. It has been 
found that Nk <  is a general criterion that should be met for good results, where 
N  is the total number of training examples [255]. Therefore, the number of effective 
nearest neighbors k  will be a free parameter in the k-nearest neighbor algorithm to 
be optimized according to test results. 
3.2.1.3 Support vector machine 
Although the basis of support vector machine had been laid in the 1960s, the 
idea of support vector machine was only officially proposed in 1995 by Vapnik and 
his co-workers [104,245]. Then, the research on its theoretical aspects and 
application aspects soared up because of the strong predictive power that this 
statistical learning algorithm had shown. It has been applied in a wide range of 
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problems including text categorization [265,266], hand-written digit recognition [104], 
image classification and object detection [267,268], flood stage forecasting [269], 
micro-array gene expression data analysis [270], drug design [158], prediction of 
protein solvent accessibility [271], protein fold recognition [272], protein secondary 
structure prediction [273], prediction of protein-protein interaction [274]. These 
studies have demonstrated that SVM is consistently superior to other supervised 
learning methods [158,270,275].  
Support vector machine (SVM) separates a given set of labeled training 
examples in a multi-dimensional space via a hyper-plane optimally positioned 
between the positive samples and negative samples. The test examples are then 
placed onto this multi-dimensional space to recognize which are positive and which 
are negative based on their relative positions to the hyper-plane. For most of 
real-world problems, the dataset can not be separated by this linear method. Special 
“kernels” are introduced in SVM to automatically conduct nonlinear mapping from the 
input space onto a high-dimensional feature space in which the training examples 
can be linearly separated. The optimal hyper-plane thus determined in the feature 
space corresponds to a nonlinear decision boundary in the input space.  




Let the training data of two separable classes, which contains n samples, be 
represented by ),(),......,,(),,( 2211 nn yxyxyx  .,...,2,1 ni = where Ni Rx ∈ is a vector 
in an N dimensional space, and iy { }1,1 +−∈ indicates class label. Given a weight 
vector w  and a bias b  (figure 3.2), it is assumed that these examples can be 
separated by a hyperplane with a margin of 1: 
1+≥+⋅ bxw i ,  for 1+=iy          Equation 3.11 
1−≤+⋅ bxw i ,  for 1−=iy          Equation 3.12 
where Tnwwww ),...,,( 21= is a vector of n  elements.  
Equation 4.11 and Equation 4.12 can be combined into a single inequality: 

















Figure 3.2: Definition of Hyperplane and Margin. The circular dots and square dots 
represent samples of class -1 and class +1, respectively. 





As shown in Figure 3.3(a), there exist a number of separating hyperplanes for an 
identical group of training data. The objective of SVM is to determine the optimal 
weight ow  and optimal bias ob  such that the corresponding hyperplane separates 
the positive and negative training data with maximum margin, which is expected to 
produce the best generalization performance. This hyperplane (Figure 3.3(b)) is 
called the Optimal Separating Hyperplane (OSH). 
The equation for an arbitrary hyperplane can be written as  
,0=+⋅ bxw iT              Equation 3.14 
and the width of the two corresponding margins is 












),(γ        Equation 3.15 
Given the constraint Equation 3.13, one obtains 
w
bw oo
2),(max == γγ            Equation 3.16 
Figure 3.3: Available separating hyperplanes and Optimal Separating Hyperplane 
(a) Available Hyperplanes H, H’, H’’,… 
(b) Unique Optimal Separation Hyperplane 
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The OSH can therefore be obtained by minimizing the norm of w  under the 
inequality constraint Equation 3.13. The saddle point of the following Lagrangian 













1),,( αα       Equation 3.17 
where 0≥iα are Lagrange multipliers. The solution to this Quadratic Programming 
(QP) problem requires that the gradient of ),,( αbwL with respect to w and 
























ii yα              Equation 3.19 
By substituting Equation 3.18 and Equation 3.19 into Equation 3.17, the QP problem 















1)( αα        Equation 3.20 






ii yα  and 0≥iα , .,...,2,1 ni =  
The points located on the two optimal margins will have non-zero coefficients 
iα  among the solutions to Equation 3.20, and are called Support Vectors (SVs). The 
bias ob  can be calculated as follows: 



















      Equation 3.21 
After determination of support vectors and bias, the decision function that 
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αα   Equation 3.22 
Real-world problem are usually nonlinear in nature. The linear classification 
scheme described above is thus inapplicable to these problems. A nonlinear 
classification scheme can be introduced such that the original training data x in the 
input space X  is projected into a high-dimensional feature space F  via a Mercer 
kernel operator K  [276,277] followed by the construction of OSH in the feature 
space (Figure 3.4).  
Mathematically, the above set of equations is transformed into the following form by 
substituting the inner product in input space )( xxi ⋅  to the inner product in feature 























Figure 3.4: Project the training data nonlinearly into a higher-dimensional feature 
space and construct a hyperplane to separate positive and negative datasets with 
maximum margin there.  









m yxyxK α   ,0≥mα         Equation 3.24 
 ∫∫ > ,0)()(),( dxdyygxgyxK   ∫ ∞< ,)(2 dxxg       Equation 3.25 
In this case, the Kernel function can represent a legitimate inner product in a feature 
space: 
 ))()((),( yxyxK Φ⋅Φ=            Equation 3.26 
where Φ  is an implicit mapping function from the input space to the feature space 
F .  






















ii yα  and 0≥iα , .,...,2,1 ni =         Equation 3.27 
Thus the decision function changes to be 
 ∑ +=
SV
oiii bxxKysignXf ]),([)( α        Equation 3.28 
 















αα    Equation 3.29 
 Linear classification can also be integrated in the non-Linear classification 
framework. By defining )(),( yxyxK T ⋅= , the equations for non-linear classification 
immediately become equations for linear classification. 
Usually, many candidate kernel functions can be used in a SVM, such as 








−−= , and others [278], as well as their combinations such as 
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the sum or tensor products of kernels. Among them, Gaussian kernel is the most 
popular one and we use Gaussian kernel in our classification. Usually, there are 
some parameters to be optimized in kernel function, such as the parameter σ  in a 
Gaussian kernel. 
3.2.2 Pre-processing for classification 
 While neglected by many machine learning research in the area of 
bioinformatics, pre-processing is regarded as a necessary step for serious real world 
data mining in the machine learning community. Here, several popular 
pre-processing techniques are explored. 
3.2.2.1 Scaling 
 One of these widely used pre-processing techniques is normalization. 
Empirically, normalization will help to improve the prediction accuracy. In this work, 
Equation 3.30 is used for normalization, which is the approach adopted by LIBSVM 









−=           Equation 3.30 
where iA  is the i -th feature, iA  is the average value of iA  among all the 
examples. After this process, all the features will be in the region of [-1,+1]. 
Another very important issue of pre-processing is dimensionality reduction. 
Bellman (1961) [280] first proposed the term “curse of dimensionality”, which refers 
to the exponential growth of hyper-volume as a function of dimensionality. Most 
statistical learning models can be thought of mappings from an input space to an 
output space. Thus, loosely speaking, a statistical learning model needs to somehow 
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"monitor", cover or represent every part of its input space in order to know how that 
part of the space should be mapped. Covering the input space takes resources, and, 
in the most general case, the amount of resources needed is proportional to the 
hyper-volume of the input space. The exact formulation of "resources" and "part of 
the input space" depends on the type of the model and should probably be based on 
the concepts of information theory and differential geometry. The curse of 
dimensionality causes a model with lots of irrelevant inputs to behave relatively badly. 
When the dimension of the input space is high, the model uses almost all its 
resources to represent irrelevant portions of the space. Even if a statistical learning 
algorithm is able to focus on important portions of the input space, the higher the 
dimensionality of the input space is, the more examples are needed to make a 
reasonable sampling. 
Dimensionality reduction has been the focus of pre-processing research for 
quite some time [281-284]. Conventional approaches have been developed to select 
the “best” subset of the original features that can best describe the problem. Recent 
advances in dimensionality reduction incorporate methods that will construct a new 
set of features from the original features to minimize the information loss when 
discarding any of the original features. Such methods are represented by Principal 
Component Analysis (PCA) and Independent Component Analysis (ICA). 
3.2.2.2 Principal component analysis 
Principal Component Analysis (PCA) is widely used in signal processing, 
statistics, and neural computing [285,286]. In some application areas, this is also 
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called the (discrete) Karhunen-Loève transform, or the Hotelling transform.  
 The basic idea in PCA is to find the components nsss ......, 21  so that they 
explain the maximum amount of variances in the input space by n  linearly 
transformed components. PCA can be defined in an intuitive way using a recursive 
formulation. Define the direction of the first principal component, say 1w , by  






          Equation 3.31 
where 1w  is of the same dimension as the example vector x . Thus the first 
principal component is the projection on the direction in which the variance of the 
projection is maximized. Having determined the first 1−k  principal components, 























xwwxwEw        Equation 3.32 
The principal components are then given by Equation 3.33.  
 xws Tii =               Equation 3.33 
In practice, the computation of the iw  can be simply accomplished using the 
(example) covariance matrix { } CxxE T = . The iw  are the eigenvectors of C  that 
correspond to the k  largest eigenvalues of C .  
By choosing the n  first components, PCA is used to reduce the dimensionality 
of the input data. One usually chooses Nn <  ( N  is the dimension of the original 
feature vector). It can be proven that the representation given by PCA is an optimal 
linear dimension reduction technique in the mean-square sense [285]. By this means, 
noise may be reduced, as the data not contained in the n  first components may be 
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mostly due to noise. A simple illustration of PCA is found in Fig. 3.5, in which the first 
principal component of a two-dimensional data set is shown.  
 
 
3.2.2.3 Independent component analysis 
 Independent component analysis (ICA) [287,288] is a statistical and 
computational technique for revealing hidden factors that underlie sets of random 
variables, measurements, or signals.  
Assume that we observe N  linear mixtures x ( NAAA ..., 21 ) (the features of an 
example) of N independent components Nsss ..., 21 , 
NjNjjj smsmsmA +++= ......2211         Equation 3.34 
In the ICA model, it is assumed that each mixture jA  as well as each 
independent component ks  is a random variable. The observed values jA ( x ), e.g., 
the j -th feature of all the examples, are then a sample of this random variable. 
Figure 3.5: Principal component analysis of a two-dimensional data set. The 
line shown is the direction of the first principal component, which gives an 
optimal (in the mean-square sense) linear reduction of dimension from 2 to 1 
dimension. 
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Without loss of generality, it is assumed that both the mixture variables and the 
independent components have zero mean: If this is not true, then the observable 
variables jA  can always be centered by subtracting the sample mean, which 
makes the model zero-mean.  
It is convenient to use vector-matrix notation instead of the sums like in the 
previous equation. The above mixing model is written as  
Msx =               Equation 3.35 
where x  is the random vector whose elements are the mixtures NAAA ..., 21 ; s  is 
the source vector with elements Nsss ..., 21 ; and M  is the mixing matrix with 
elements ijm .  
The statistical model in Equation 3.36 is called independent component analysis, 
or ICA model. The ICA model is a generative model, which means that it describes 
how the observed data are generated by a process of mixing the components js . 
The independent components are latent variables, meaning that they cannot be 
directly observed. Also the mixing matrix is assumed to be unknown. All we observe 
is the random vector x , and we must estimate both M  and s  using it. This must 
be done under assumptions as general as possible.  
Wxs =               Equation 3.36 
The starting point for ICA is the very simple assumption that the components js  
are statistically independent. It is assumed that the independent component must 
have non-gaussian distributions. However, in the basic model we do not assume that 
these distributions are known. For simplicity, it is also assumed that the unknown 
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mixing matrix M  is square. Then, after estimating the matrix M , its inverse 
W can be computed.  
The non-gaussianity can be measured in different ways. Suppose y  is a 
random variable, classical measure of non-gaussianity is kurtosis which is defined by 
Equation 3.37: 
{ } { }( )224 3)( yEyEykurt −=          Equation 3.37 
A second very important measure of non-gaussianity is given by negentropy. 
Negentropy is based on the information-theoretic quantity of (differential) entropy. 
Entropy E  is defined for a discrete random variable y  as 
 )(log)()( 2 i
i
i ayPayPyE ==−= ∑         Equation 3.38 
where the ia  are the possible values of y . This very well-known definition can be 
generalized for continuous-valued random variables, in which case it is often called 
differential entropy. The differential entropy E  of a random variable y  with density 
)(yf  is defined as [289]: 
dyyfyfyE )(log)()( 2∫−=           Equation 3.39 
A fundamental fact in information theory is that a gaussian variable has the 
largest entropy among all random variables of equal variance. To obtain a measure 
of non-gaussianity that is zero for a gaussian variable and always nonnegative, one 
often uses a slightly modified version of the definition of differential entropy, called 
negentropy. Negentropy J  is defined as follows: 
 )()( yEyEJ Gauss −=            Equation 3.40 
where Gaussy  is a Gaussian random variable sharing the same covariance matrix as 
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y . However, negentropy is computationally very difficult. Estimating negentropy 
using the definition would require an estimate (possibly nonparametric) of the 
probability density function. Therefore, simpler approximations of negentropy are 
very useful, for example Equation 3.41 [290]. 







2)()(          Equation 3.41 
where ik  are some positive constants, and v  is a Gaussian variable of zero mean 
and unit variance. The variable y  is assumed to be of zero mean and unit variance, 
and the functions iG  are some non-quadratic functions [290]. The following choices 
of G have been proved useful:  
 ay
a
yG coshlog1)( =  where 21 ≤≤ a  and      Equation 3.42 
 )2/exp()( 2yyG −−=            Equation 3.43 
By choosing an appropriate G  the classical kurtosis measure of non-gaussianity 
can be unified in this framework, i.e. 4)( yyG = . 
Equation 3.41 is used as the contrast function (non-gaussianity measure) to be 







          Equation 3.44 
Thus the first independent component is the projection on the direction in which 
the non-gaussianity (measured by an approximation of negentropy) of the projection 
is maximized. To estimate several independent components, several units with 
weight vectors Nwww ......, 21  need to maximized together using Equation 3.44. To 
prevent different vectors from converging to the same maxima, the outputs are 
decorrelated after every iteration of the optimization process. The independent 
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components are then given by Equation 3.45.  
 xws Tii =               Equation 3.45 
ICA can be seen as an extension to principal component analysis and factor 
analysis. ICA is a powerful technique capable of finding the underlying factors or 
sources. It is interesting to note that ICA makes explicit connection to projection 
pursuit. Projection pursuit is a technique developed in statistics for finding 
“interesting” projections of multidimensional data [291-294]. Such projections can 
then be used for decision making, and for such purposes as density estimation and 
regression. In basic (one dimensional) projection pursuit, we try to find a direction 
such that the projections of the data in this directions have an interesting distribution, 
i.e., display some structure. It has been argued by Huber [293] and by Jones and 
Sibson [294] that the Gaussian distribution is the least interesting one, and that the 
most interesting directions are those that show the least Gaussian distribution. This 
is exactly how to estimate the ICA model. The usefulness of finding such projections 
can be seen in Fig. 4.6, where the projection on the projection pursuit direction, 
which is horizontal, clearly shows the clustered structure of the data. The projection 
on the first principal component (vertical), on the other hand, fails to show this 
structure.  
So far, there are no reported indicators that can show whether a statistical 
learning algorithm or a pre-processing procedure is suitable for a certain application. 
The performances of different classifiers and the effect of scaling, PCA and ICA on 
them are evaluated and compared below. 






3.3 Problem definition 
The input data to the above statistical learning methods are a set of examples 
(training set) and the class labels attached to these examples (training labels). The 
accuracy of the output models can be evaluated by comparing the model predictions 
on a set of different examples (testing set) with prior knowledge of the class labels of 
these examples (testing labels). In the majority of cases, there are some free 
parameters in statistical learning algorithms which control the generation of models, 
such as the prune level in decision tree induction and the kernel parameter in 
support vector machine. The “best” model is usually selected from a series of models 
generated using different parameter sets according to certain model accuracy 
measurements. This leads to the problem that the selection of the “best” model is not 
independent of the testing set. Therefore, the best model may “over-fit” to a 
Figure 3.6: An illustration of projection pursuit and the “interestingness” of 
non-gaussian projections.  
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particular testing set. In order to have an unbiased estimation of the prediction 
accuracy of the selected models, an independent evaluation data set with known 
class labels, in addition to the training and testing data sets, is needed. The unbiased 
estimation of the prediction accuracy of the selected model can therefore be 
measured on the independent evaluation data set. The procedures used to construct 
the data sets and the measurements used to evaluate the model accuracy are 
detailed below. 
3.3.1 Description of data 
All drug-target protein sequences used in this study are retrieved from the 
SWISS-PROT database release 40 [295]. A total of 339 human target proteins are 
obtained by an automated sequence retrieval program linked to therapeutic target 
database. These proteins are labeled “+1”. The non-drug-target proteins are 
composed of 1620 other proteins randomly selected. These proteins are given the 
label “-1”. As shown in Table 3.1, the training set is comprised of 235 positive 
examples and 1131 negative examples; the testing set is comprised of 64 positive 
examples and 301 negative examples; and the independent evaluation set is 
comprised of 40 positive examples and 188 negative examples. A perl program is 
written to randomly distribute these proteins while maximizing the protein family 
diversity [296] in each set. The proportions of positive examples in all the three data 
sets are close to 17%, which is the expected proportion of targets in human genome 
(5,000 / 30,000) [89].  
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Table 3.1: Composition of training, testing and independent evaluation data sets. 
 
Data Set  No. of positive examples No. of negative examples
Training set 235 1131 
Testing set 64 301 
Independent evaluation set 40 188 
 
Training and testing of the statistical learning model requires each example be 
represented as a feature vector consisting of a fixed number of real valued 
components. These feature vectors are assembled from the encoded representations 
of tabulated residue properties including amino acid composition, hydrophobicity, 
normalized Van der Waals volume, polarity, polarizability, charge, surface tension, 
secondary structure and solvent accessibility for each residue in the sequence 
[271-274,297]. Three types of descriptors, composition (C), transition (T) and 
distribution (D), are used to describe global composition of each of these 
properties[298]. C is the number of amino acids of a particular property (such as 
hydrophobicity) divided by the total number of amino acids. T characterizes the 
percent frequency with which amino acids of a particular property is followed by amino 
acids of a different property. D measures the chain length within which the first, 25, 50, 
75 and 100% of the amino acids of a particular property is located respectively.  




A hypothetical protein sequence AEAAAEAEEAAAAAEAEEEAAEEAEEEAAE, 
as shown in Figure 3, has 16 alanines ( 161 =n ) and 14 glutamic acids ( 202 =n ). The 
composition for these two amino acids are %33.53)/( 211 =+ nnn and 
%67.46)/( 212 =+ nnn  respectively. There are 15 transitions from A to E or from E to 
A in this sequence and the percent frequency of these transitions is (15/29)=51.72%. 
The first, 25, 50, 75 and 100% of “A” are located within the first 1, 5, 12, 20 and 29 
residues, respectively. The D descriptor for “A” is thus 1/30=3.33%, 5/30=16.67%, 
12/30=40.0%, 20/30=66.67%, 29/30=96.67%. Likewise, the D descriptor for “E” is 
6.67%, 26.67%, 60.0%, 76.67%, 100.0%. Overall, the amino acid composition 
descriptors for this sequence are C=(53.33, 46.67), T=(51.72) and D=(3.33, 16.67, 
40.0, 66.67, 96.67, 6.67, 26.67, 60.0, 76.67, 100.0), respectively. 
Descriptors for other properties can be computed by a similar procedure and all 
the descriptors are combined to form the feature vector. In most studies, amino acids 
are divided into three classes for each property and thus the three types of 
descriptors for each property consist of 21 elements: three for C, three for T and 15 
for D. Taking hydrophobicity as an example, the steps of feature construction are as 
Figure 3.7: A hypothetical sequence for illustration of derivation of the feature
vector of a protein. 
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follows: first, 20 aminoacid residues can be devided into three groups according to 
their hydrophobicity (denoted as H, M, L). The original protein sequence can thus be 
translated to a pseduosequence of H, M and L according this grouping. Then, the 
composition of H, M and L (3 elements), transitions of H/M, H/L and M/L (3 elements), 
and distributions of H, M, and L (15 elements) can be computed. They add up to 21 
elements. The physicochemical properties of amino acid residues are can be found 
in KEGG database. The secondary structure and solvent accessibility properties of 
each residue are predicted by the PHD program. Details of the formula can be found 
in the respective publications and references therein[271-274,297,298]. These 
properties and their respective dimensionality are given in Table 3.2. All the features 
are continuous and the total dimensionality of the vector is 188 (all the vectors are 
column vectors by default in this work). 
 
Table 3.2: Feature vector composition. 
 
Feature description No. of dimensions 
Amino acids composition 20 
Hydrophobicity 21 




Surface tension 21 
Secondary structure 21 
Solvent accessibility 21 





3.3.2 Measurements of prediction accuracy 
Before discussing the result of the drug-target like protein prediction, it is 
important to explain the measurements used to evaluate the effectiveness of a 
classification algorithm. First, confusion Matrix is the most simple and informative 
way to analyze the behavior of a classifier. It contains information about both actual 
and predicted classifications. Table 3.3 shows a common confusion matrix for binary 
classification, in which “a” is the number of correctly classified positive examples, 
called true positive (TP); “d” is the number of correctly classified negative examples, 
called true negative (TN); “b” is the number of incorrect predictions of the positive 
class, called false positive (FP); “c” is the number of incorrect predictions of the 
negative class, called false negative (FN).  
 




Positive a (TP) b (FP) 
Predicted 
Negative c (FN) d (TN) 
 
Based on the confusion matrix, accuracy measurements of a classifier can be 
calculated by the following quantities. 
1. Overall accuracy, A  for short, is the proportion of the total number of 
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predictions that are correct. It is calculated using Equation 3.1. 
)/()( dcbadaA ++++=          Equation 3.1 
2. Precision, P  for short, is the proportion of the predicted positive examples 
that are correct. It is calculated using Equation 3.2. 
)/( baaP +=              Equation 3.2 
3. Recall, R  for short, is the proportion of the real positive examples that are 
correctly predicted. It is calculated using Equation 3.3. 
)/( caaR +=             Equation 3.3 
4. F value, F  for short, is designed to have a balanced evaluation on both 
precision and recall. It is the geometric mean of R  and P , as in Equation 3.4. 
)/(**2 RPRPF +=            Equation 3.4 
The most commonly used measurement for evaluating a classifier is the overall 
accuracy. However, it is usually found that positive examples are more interesting. 
For example, in our case, finding a drug-target like protein is of more interest to 
pharmaceutical companies than finding a protein that is unlikely to be a drug target. 
Under this situation, the precision and recall, which reflects the prediction accuracy 
on positive examples, are important measurements. Precision gives the idea about 
how much confidence we have when the model gives a positive prediction and recall 
measures how many real positive examples are predicted by this model. The 
geometric average of precision and recall, F value, is a balanced view of these two 
factors. 
The data sets in this application are not balanced. The number of negative 
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examples is around five times bigger than that of positive examples. Therefore, the 
prediction accuracy on negative examples will have five times more influence on the 
overall accuracy. Inspired by the F value, we devised a new measure “balanced 
precision” in this work, which is the geometric mean of the precision on positive 
examples and the precision on negative examples. Balanced precision is denoted by 
G  and can by calculated by Equation 3.5: 
)/(**2 RRNRRNG +=  where )/( bddRN +=      Equation 3.5 
In this work, the statistical models are selected according to three criteria, A , F  
and G , respectively. 
As discussed above, the free parameters controlling the generation of the 
statistical models needs to be optimized. In this work, a series of models are 
generated using different parameters. We define the term “best A ” of a learning 
algorithm as the A  measured on an independent evaluation set using the same 
parameter set that maximizes A  on the testing data set. The “best F ” and “best 
G ” are defined similarly as the measurements made on the independent evaluation 
set using the same parameter sets that maximize them on the testing data set 
respectively. Note, under this definition, the “best” measurements might not be the 
highest values achieved on the independent evaluation set. 
Furthermore, we consider one algorithm to be better than another if and only if 
this algorithm wins two or more times when its best A , best F  and best G  are 
compared to those of the other algorithm respectively. Also, we say one model is 
“better” than another if and only if two or more of its three measurements ( A , F  
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and G ) are better than those of the other. 
 
3.4 Prediction of drug-target like proteins 
In order to evaluate different classification and pre-processing techniques, an 
efficient tool to implement different algorithms is needed. The matrix operation 
support provided by MatLab [299] makes the representation of numerical data and 
implementation of the different algorithms much easier. Therefore, we choose 
MatLab as our platform of computation. 
With the help of standard MatLab matrix functions and standard toolboxes, i.e. 
statistics toolbox and optimization toolbox, we implemented the algorithms for 
scaling, PCA, decision tree, k-nearest neighbor, and support vector machine. An ICA 
package for MatLab, FastICA 2.1, was used for ICA analysis, which is developed by 
Jarmo Hurri et.al. [300] and can be downloaded freely from 
http://www.cis.hut.fi/projects/ica/fastica/. 
The decision tree algorithm was implemented with the information gain 
branching criterion. This is because the gain ratio criterion is mainly designed to deal 
with attributes with many discrete values. In our case, all the attributes are 
continuous where a threshold is chosen to bisect all the possible values, which is 
equivalent to all the attributes having two discrete values. Therefore, it is not 
necessary to use the gain ratio branching criterion. And our later study also 
confirmed that the gain ratio criterion performed no better than the information gain 
criterion. 
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−−= . This is because the Gaussian kernel always performs 
better than others in our previous study of protein function classification [275,301].  
In the ICA analysis, the nonlinearity function used in the non-gaussianity 
measurement was 3)( uuG = , which is the default choice of the FastICA package. 
 All the programs in this work were developed using MatLab R13 licensed from 
NUS and executed on a Dell Optiplex GX240 computer with one 2.4GHz Intel 
Pentium IV CPU and 512M memory. 
3.4.1 Decision tree prediction 
 After training with the training data set without any pre-processing, the decision 
tree that perfectly classifies the training set is pruned from level 0 (original tree) to 
the maximal level (only the root is kept). By the definitions in section 3.3.2, the best 
A , F , and G  achieved by the decision trees pruned in different levels are 85.09%, 
54.05% and 68.40% respectively, which are shown in Figure 3.7. 
The pre-process of scaling does not affect the tree induction because the 
decision tree induction algorithm only cares about the relative order of the attribute 
values when selecting the thresholds to bisect the continuous attributes. Therefore, 
the scaled data sets give the same tree and the same performance.  
In order to evaluate the effect of the PCA dimensionality reduction, the first n  
principal components of the original data sets are selected to construct a new set of 
training, testing and independent evaluation data and the decision tree algorithm is 
evaluated on the new set of data with reduced dimensionality. Here, n  is scanned 
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from 1 to the maximal number of principle components with an interval of 10. The 
best A , best F , and best G  achieved using different numbers of principal 
components are plotted in Figure 3.8. Overall, The best A , best F , and best G  
achieved, as shown in Table 3.5, are 79.39%, 43.37% and 46.62% respectively 
which is worse than those of the original or scaled data sets. 
Similar to PCA, the evaluation of the effect of ICA dimensionality reduction on 
decision tree induction is conducted. The first n  independent components of the 
original data sets were first estimated to construct a new set of training, testing and 
independent evaluation data. The decision tree algorithm is then evaluated on the 
new set of data with reduced dimensionality. The best A , best F , and best G  
achieved using different numbers of independent components are plotted in Figure 
4.9. As shown in Table 4.6, the best A , best F , and best G  achieved are 81.58%, 
22.78% and 35.25% respectively, which are also inferior to those of the original or 
scaled data sets. 
In summary, the decision tree algorithm works better on original or scaled data 
sets. The best A , best F , and best G  achieved are 85.09%, 54.05% and 
68.40% respectively.  
3.5.2 K-nearest neighbor prediction 
  
 




Table 3.4: Summary of the decision tree performance on original or scaled data sets. 












13 0.8509 0.2609 0.2609 
F Value 4 0.8509 0.5405 0.6493 
Balanced 
Precision 

















































Figure 3.7: Decision tree prediction of drug-target like proteins on original datasets.


















90 0.7939 0.3864 0.5633 
F Value 60 0.8070 0.4337 0.5925 
Balanced 
Precision 






















































Figure 3.8: Decision tree prediction of drug-target like proteins after PCA 
dimensionality reduction. 



















110 0.8158 0.2667 0.4422 
F Value 130 0.7982 0.2278 0.3550 
Balanced 
Precision 






















































Figure 3.9: Decision tree prediction of drug-target like proteins after ICA 
dimensionality reduction. 
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On the original and scaled data sets, the parameter k  used in kNN is scanned 
in the range of 1…37. The number 37 is calculated as the square root of the number 
of training examples. The kNN algorithm performs slightly better on original data sets. 
The best A , best F , and best G  on original data sets are 83.77%, 50.00% and 
69.64% respectively, which is comparable to those of decision trees. The 
classification results on original data sets are plotted in Figure 3.10 and summarized 
in Table 3.7. 
The effect of PCA dimensionality reduction on kNN classification is evaluated 
similarly as in the last section. The first n  principle components of the original data 
sets are estimated to construct a new set of training, testing and independent 
evaluation data and the kNN algorithm is evaluated on this new set of data with 
reduced dimensionality. The number of principal components n  is scanned from 1 
to the maximum with an interval of 10. The best A , best F , and best G  achieved 
using different numbers of principal components are 83.77%, 56.84% and 75.30% 
respectively. These values are better than those of the original data sets. These 
results are plotted in Figure 3.11 and summarized in Table 3.8. Also, it is interesting 
to see the best models are built when only a small number of principal components, 
i.e. less than one third of the total dimensions, are used in the training, testing and 
independent evaluation data sets.  
 
 

















23 0.8377 0.2449 0.2603 
F Value 1 0.7895 0.5000 0.6964 
Balanced 
Precision 
















































Figure 3.10: K-nearest neighbor prediction of drug-target like proteins using 
original data sets. 

















30 0.8377 0.4127 0.7330 
F Value 50 0.8333 0.5684 0.7429 
Balanced 
Precision 





















































Independent evaluation data 
Figure 3.11: K-nearest neighbor prediction of drug-target like proteins after PCA 
dimensionality reduction. 


















160 0.7939 0.3621 0.6027 
F Value 140 0.7851 0.3276 0.5649 
Balanced 
Precision 
























































Independent evaluation data 
Figure 3.12: K-nearest neighbor prediction of drug-target like proteins after ICA 
dimensionality reduction. 
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The ICA pre-processing is also evaluated similarly. The best A , best F , and 
best G  are plotted in Figure 3.12 against the number of independent components 
used. As shown in Table 3.9, the best A , best F , and best G  achieved using 
different number of independent components are 79.39%, 32.76%, and 56.49% 
respectively, which is also better than the original results. 
In summary, the k-nearest neighbor algorithm works best on PCA pre-processed 
data sets. The best A , best F , and best G  achieved are 83.77%, 56.84% and 
75.30% respectively. These results are slightly better than those of decision trees. 
 
3.5.3 Support vector machine prediction 
 On original data sets, SVMs are trained with the kernel parameter σ  scanned 
in the range of [1...75] with an interval of 1, which is the range that empirically gives 
optimal classification results in protein function classification [275]. The 
measurements concerned, A , F  and G , are plotted against σ  in Figure 3.13. 
The best A , best F , and best G , as summarized in Table 3.10, are 87.28%, 
56.72%, and 72.47% respectively. 
On scaled data sets, the kernel parameter σ  is scanned in the range of 
[0.04..3] with an interval of 0.04. The A , F , and G  obtained with different σ  are 
plotted in Figure 3.14. The best A , best F , and best G  are found in a single SVM 
model with 28.1=σ , which are 89.91%, 68.49%, and 75.63% respectively. These 
results are better than those of the original data sets.  


















27 0.8728 0.5672 0.6350 
F Value 27 0.8728 0.5672 0.6350 
Balanced 
Precision 
















































Independent evaluation data 
Figure 3.13: Support vector machine prediction of drug-target like proteins on 
original data sets. 


















1.2800 0.8991 0.6849 0.7563 
F Value 1.2800 0.8991 0.6849 0.7563 
Balanced 
Precision 
1.2800 0.8991 0.6849 0.7563 
 
 













































Independent evaluation data 
Figure 3.14: Support vector machine prediction of drug-target like proteins on 
scaled data sets. 


















130 0.8991 0.6849 0.7563 
Best F Value 130 0.8991 0.6849 0.7563 
Best Balanced 
Precision 





















































Independent evaluation data 
Figure 3.15: Support vector machine prediction of drug-target like proteins after 
PCA dimensionality reduction. 


















140 0.8772 0.5634 0.7046 
Best F Value 130 0.8509 0.5385 0.6657 
Best Balanced 
Precision 






















































Independent evaluation data 
Figure 3.16: Support vector machine prediction of drug-target like proteins after 
ICA dimensionality reduction. 
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The effect of PCA dimensionality reduction on SVM prediction is evaluated in a 
similar way as that discussed in the previous sections. The number of principal 
components estimated is scanned from 1 to the maximum with an interval of 10 and 
the kernel parameter σ is scanned in different ranges that empirically give optimal 
results under different conditions. The best A , best F , and best G  achieved 
using different numbers of principal components are plotted in Figure 3.15. Overall, 
The best A , best F , and best G  achieved with different numbers of principal 
components, as shown in Table 3.12, are 89.91%, 68.49%, and 77.30% respectively, 
which are comparable (slightly better in terms of balanced precision) to those on the 
scaled data sets. 
The effect of the ICA dimensionality reduction on SVM is also evaluated. The 
number of independent components estimated is scanned from 1 to the maximum 
with an interval of 10 and the kernel parameter σ  is scanned in different ranges 
which empirically give optimal solutions while different numbers of independent 
components are used. The best A , best F , and best G  achieved are plotted 
against the number of independent components in Figure 3.16. As shown in Table 
3.13, the best A , best F , and best G  achieved, are 87.72%, 53.85%, and 
66.57% respectively, which are not as good as those of the original data sets. 
In summary, SVM performance can be improved by the pre-processing of 
scaling and PCA. Among all the three classification techniques explored, SVM 
classifies our data best. The best A , best F , and best G , if optimized individually, 
can reach 89.91%, 68.49% and 77.30% respectively.  
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3.6 Prediction results and analysis 
Table 3.14 summarizes the comparison between different statistical learning 
methods evaluated in this work. Overall, SVM gives the best results with the best A , 
best F , and best G  reaching 89.91%, 68.49% and 77.30% in different SVM 
models. The accuracy of SVM prediction, if successfully generalized in real-world 
application, is reasonably good to provide valuable information for genome scale 
target discovery.  
 











85.09% 83.77% 89.91% 
Best F Value 54.05% 56.84% 68.49% 
Best Balanced 
Precision 
68.40% 75.30% 77.30% 
 
 
Errors in statistical learning arise for a number of reasons. It is not expected that 
exhaustive experiments have been done to verify whether each known protein is a 
target or not. Also, the therapeutic targets collected in TTD are not complete. This 
may result in that, with a small possibility, some drug targets are included in the 
negative examples. Although, most of the statistical learning methods are able to 
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deal with a certain level of noise, these approaches are generally based on a large 
number of observations (examples). Here in our application, the number of positive 
examples used for training is only 235, which accounts for less then 5% of the 
expected population of drug-target like proteins. Therefore, these wrongly assigned 
class labels, if any, may considerably confuse the learning algorithm and 
compromise the accuracy of the constructed classification models. 
Also, the training data are not balanced. The number of negative examples is 
significantly higher than that of positive examples. It is expected that the negative 
examples represent a better sample of the problem space and provide more 
comprehensive information about its classification. Our results indeed show 
significantly better performance on negative examples than on positive examples. 
For example, while one SVM model has an overall accuracy of 89.91%, its F value is 
only 68.49%. 
Anticipated rapid progress in pharmaceutical sciences is expected to provide 
larger number of and more accurate training examples. Knowledge from study of 
protein functions also facilitates the selection of training examples for prediction of 
potential drug-target like proteins. 
According to the principal of Occam’s razor, the simpler a model is, the better it 
will generalize. However, too simple models may not catch all the essential 
characteristics of a problem. The following inequality was found to describe this 
relationship during the development of the support vector machine algorithm. With 
the probability of η−1  ( 10 ≤≤η ), the following bound holds for all models α  that 
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 ++≤ ηαα      Equation 4.46 
where h  is a measure of the model complexity called the Vapnik-Chervonenkis (VC) 
dimension, l  is the number of training examples and )(αempR  is the empirical risk 











1)( αα          Equation 4.47 
where ),( αxf  is the classification function used for a model α , ix  is the i -th 
training example and iy  the corresponding class label. Therefore, a good statistical 
learning method shall strike a balance between the model complexity and the 
empirical risk. 
The better performance displayed by support vector machine might be partly 
explained with the above theorem. By implementing a scheme called Structural Risk 
Minimization (SRM), SVM finds the optimal separation hyper-plane, which proves to 
be the model with lowest complexity when the empirical risk is fixed. 
In comparison, the decision tree induction process does not guarantee the result 
to be the simplest tree, whether in terms of tree height or number of decision nodes. 
The decision tree induction process always branches on the candidate attribute that 
gives the maximal information gain. Therefore, it can be regarded as a greedy 
search algorithm to build a tree as simple as possible. As we know, the greedy 
search algorithm usually does not guarantee the finding of the global minimal. On the 
other hand, although the information gain criterion used in selecting branching 
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attributes well reflects the nature of classification – find the class information that is 
hidden in a number of attributes, the binary discretization method used to deal with 
continuous attribute may not well reflect the class information hidden in an attribute. 
This binary discretization will work well when the attribute values of each class have 
only one center. If the attribute values of each class have multiple clusters 
(sub-classes), this binary discretization method will overlook much useful information 
by combining those multiple clusters into one. A good discretization process needs to 
separate the attribute into multiple segments that generate maximum gain ratio. 
However, it would be computationally too expensive to afford as the search for the 
best number of segments and their boundaries will have to evaluate 12 1 −−n  
possible solutions, where n  is the number of places where adjacent examples 
belong to different classes. 
In comparison to the decision tree algorithm, the algorithm of kNN works well 
with attribute values that have multiple clusters. However, this advantage can only be 
fully displayed when the problem space is well sampled and every sub-cluster (or 
sub-class) of each class is well represented by training examples. However, this is 
not likely to be our case – the examples of the two classes display no obvious 
structure on any of the dimensions and 1366 training examples can by no means 
sample a space of 188 dimensions well. Even if the input space is reduced to only 50 
dimensions, the training examples are still far from enough to sample the input space. 
This kind of insufficient sampling will carry more information on a particular sample 
set (training set) besides the information on the attribute-class relationship. An 
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algorithm that is less selective may therefore tend to use more irrelevant information 
to build the classification model.  In other words, the constructed model may easily 
“over-fit” to that particular sampling of training examples and its expected prediction 
accuracy will be compromised. While SVM implements SRM to avoid over-fitting, the 
distance measure used in kNN is too simple to effectively avoid this over-fitting, 
which may be one of the reasons that explains the better performance of SVM over 
kNN. Future advances in small sample statistics might provide better learning 
algorithms to derive attribute-class relationship from a small number of samples in a 
high-dimensional space. 
The performance of classification may also be improved with the advances in 
the formulation of protein sequence descriptors. Although our test results 
demonstrated this set of descriptors are useful, they may not be perfect.  
Obviously, the descriptors used here do not have any direct logical connection to 
the drug-target likeness. For example, descriptors that reflect the sequence 
uniqueness and function relationship may give better information on the drug-target 
likeness. It is desirable for such quantitative descriptors to be devised.  
Also, the descriptors are not independent, which means the same information is 
given in more than one descriptor, which gratuitously increases the complexity of 
input space and consumes more “resources” of a statistical model. As shown in 
Figure 3.17, about 50 principal components are able to represent 90% of the total 
variances in all 188 dimensions, and 140 principal components can represent 99.9% 
of the total variances in all dimensions. However, in this application, mere PCA or 
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ICA dimensionality reduction approach seems not effective in improving the 
predictive accuracy. This might be explained by the unsupervised nature of these 
dimensionality reduction approaches. PCA and ICA do not use the class information 
when they are making linear combinations of attributes. Therefore, the constructed 
principal components or independent components may not be so relevant to the 
problem of classification. When the attributes-class relationship is intricate and the 
input space is insufficiently sampled, such as in our application, dimensionality 
reductions by mere PCA or ICA analysis may not preserve enough information 
relevant to classification. In this regard, dimensionality reduction processes that take 


































Figure 3.17: Number of principal components and the percentage of total variance 
they can represent. 




A number of statistical learning methods and pre-processing techniques are 
investigated for the application of drug-target like protein prediction, which includes 
the learning algorithms of decision tree, k-nearest neighbor and support vector 
machine and the pre-processing techniques of scaling, PCA and ICA dimensionality 
reduction. The support vector machine approach gives the best classification results. 
Scaling and PCA help to improve the performance of SVM. The highest A , F  and 
G  achieved in different SVM models reach 89.91%, 68.49% and 77.30% 
respectively. This accuracy seems to be reasonably good to facilitate the genome 
scale drug target discovery. 
Performance and applicability of the statistical learning methods may be further 
improved by incorporation of new information from advances in pharmaceutical 
sciences, proteomics, and protein function. Efficiency and accuracy of statistical 
learning methods in prediction of drug-target like proteins can also be enhanced from 
new progress in learning algorithms, descriptors, and pre-processing techniques. 
Apart from discovery of new drug targets, discovery of efficient therapeutic 
intervention strategies that explore the synergies between existing targets is also 
critical in facilitating the combat against diseases. With the help of the therapeutic 
target database, it may also be possible to explore the unknown therapeutic 
mechanisms of effective herbal medicines, which is discussed in the next chapter.






In silico study of the mechanisms of action of active 
ingredients from medicinal plants 
 
 Therapeutic mechanisms of effective herbal medicines are very useful in 
designing novel therapeutic intervention strategies. So far, medicinal plants still 
serve as a major source of novel therapeutic mechanisms. The molecular 
mechanism related to therapeutic effects of a medicine can be probed if its 
therapeutic targets can be identified. In silico approaches to study mechanisms of 
the therapeutic action of herbal medicines are developed in this endeavor. So far, 
one extended docking approach, INVDOCK, has been developed to facilitate such 
studies. Our results on nine selected active ingredients derived from herbs showed 
that over half of the INVDOCK identified potential therapeutic targets of the selected 
active herbal ingredients have relevant experimental findings, and about 70% of their 
therapeutic implications have been reported to occur in cultivated cells, animal 
models or clinical trails. These results suggest the usefulness of in silico tools in 
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Novel therapeutic mechanisms discovered from studies of MP ingredients have 
routinely been used to derive new therapeutic intervention approaches [105]. 
However, so far, studies on the therapeutic mechanism of herbal medicines are still 
very limited. 
Medicinal plants (MPs) have been widely explored in traditional medicines 
[302-304] and in drug discovery [106-108]. Approximately one third of the top-selling 
drugs currently in the market were derived from plants [108]. Because of their broad 
structural diversity and wide range of known pharmacological activities, MPs have 
served and are still used as a valuable source for new drug discovery [106-108]. 
As part of the new drug discovery effort, a large number of ingredients have 
been extracted from MPs and other natural sources, and they have been studied for 
their potential therapeutic effects[305-309]. However, the basic and clinical 
pharmacology is known for only a portion of these ingredients [305,309]. Thus the 
insufficient mechanistic understanding of MPs hinders the efforts of developing new 
drugs based on the novel therapeutic mechanisms of MP ingredients. It also limits 
the scope of therapeutic exploration of MPs used in traditional medicines and other 
herbal medicines. Hence much more research remains to be done in order to probe 
the mechanisms of action of MP active ingredients. Systematic study of the 
mechanisms of a large number of MP ingredients by means of traditional assay 
based methods is a costly and time-consuming process due to the difficulties in 
extraction, synthesis, and activity test of herbal ingredients. Therefore alternative 
approaches for low-cost and rapid analysis of the mechanisms of MP ingredients are 
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useful for the study and exploration of MPs.  
 
4.2 In silico methods for target identification of MP ingredients 
The molecular mechanism related to the therapeutic effects of an MP ingredient 
can be probed if its therapeutic targets can be identified. Target identification is also 
an important step in rational drug design [238,310]. Thus varieties of target search 
strategies have been explored or are under consideration.  
A popular approach is to derive target information from the variation of 
micro-array expression data between normal cells and cells in disease states [109]. 
Micro-array technology relies on the hybridization properties of nucleic acids to 
monitor DNA or RNA abundance on a genomic scale. By arraying different 
immobilized probe oligo-nucleotides on a chip, micro-arrays have revolutionized the 
study of genomes by allowing researchers to study the expression of thousands of 
genes simultaneously. The ability to simultaneously study thousands of genes under 
a host of differing conditions presents an immense challenge in the fields of 
computational science and data mining. Conventionally, t-test is used to identify 
those genes that have a significantly different expression level in normal and 
disease states. Now various computational methods have been used to facilitate the 
analysis of micro-array expression data to find the genes that act differently and the 
patterns of gene expression that strongly relate to certain kinds of disease 
conditions. Such approaches include regularized t-test based on a Bayesian 
statistical framework, neural networks, principal component analysis, Bayes belief 
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networks, clustering, mixture models and expectation minimization, gene shaving, 
support vector machine, hidden markov model (HMM), and other statistical learning 
methods [311,312]. For instance, statistical methods were exploited to find 
schizophrenia associated genes [238] and diffuse large B-cell lymphoma related 
genes [313] based on microarray expression data. These comparative methods may 
be potentially used for facilitating the search of the targets of MP ingredients by 
analysis of the change of expression profiles induced by the addition of specific MP 
ingredients into disease-state cells.  
High-throughput screening has been routinely used for the identification of small 
molecule drugs of a specific target [110]. The same technology can be readily 
applied to the search of targets of MP ingredients as well as synthetic chemicals. A 
comprehensive library of potential targets can be built and used for the search of 
targets [90]. It has been reported that protein chips [314] are capable of large-scale, 
high-throughput analysis of protein-small-molecule interactions. Similar to DNA 
micro-arrays, in protein chips, proteins are prepared, densely arrayed on the surface 
of the chip in their active conformations. This technology enables the large-scale 
parallel analysis of the binding affinity between a pool of proteins and a certain 
chemical, which makes it feasible to screen a target library for those proteins 
targeted by MP ingredients. Production, segregation, purification and immobilization 
of proteins required for the fabrication of protein chips is still a complex and costly 
procedure. Therefore, in silico virtual screening is expected to be a potentially good 
choice for low-cost and efficient search of targets of MP ingredients.  
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One of the widely used virtual screening approaches in rational drug design is 
quantitative structure activity relationship [58,315]. As discussed in previous 
sections, QSAR is based on the statistical analysis of the relationship between 
biological activity of a chemical and its quantitative and structural properties. The 
derived statistical model could then be used to predict the activity of an unknown 
chemical by its quantitative attributes usually calculated from its structure. By 
generating QSAR models of a sufficient pool of potential targets, this method can be 
extended to facilitate the search of the protein targets of an MP ingredient as well as 
a synthetic chemical. Specific targets can be identified from this pool if the molecule 
is predicted to have sufficient activities.  
QSAR is a target specific approach which requires the construction of a unique 
model for each potential protein target, which makes it a complex matter to screen a 
large number of potential targets. An interesting alternative method has recently 
emerged which overcomes the difficulty of using QSAR. It has been reported that 
support vector machine, an relatively new statistical learning algorithm, may be used 
to construct a universal model for prediction of the binding affinity between a protein 
and a compound using the quantitative descriptors constructed from both the protein 
sequence and the chemical structure properties [316]. This method may be easily 
extended to screen a target library to identify potential protein targets of MP 
ingredients. However, this approach requires sufficiently diverse and accurate 
known ligand-protein binding affinities in order to satisfactorily train the statistical 
learning model. A database of theoretically computed ligand-receptor binding 
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energies [317] has been used as the training examples in the previous work, which 
limits the reliability of the models generated. Hopefully, further developments of this 
method will enable it to become a useful tool for target identification. 
Ligand-protein docking is also a popular virtual screening technology in rational 
drug design. In this approach, a chemical is structurally and chemically placed into 
the binding site of a protein based on the 3D structure of both molecules and the 
computed interaction energy between them [39-41]. Testing results on a number 
chemicals have consistently indicated that they are capable of finding the 
protein-small-molecule binding conformations at a receptor site close to 
experimentally determined structures[39-41]. Thus the ligand-protein docking 
method can be readily extended to identify therapeutic targets of MP ingredients as 
well as synthetic chemicals based on the structural and molecular mechanical 
analysis of the bindings between the molecules and the therapeutic targets collected 
in TTD [318]. So far, an extended ligand-protein docking method, INVDOCK, has 
been specifically used for automated drug target identification of several small 
molecules [111]. 
 
4.3 A closer examination of an in silico method - INVDOCK 
INVDOCK is the only in silico method specifically applied to identification of 
protein targets of small chemicals so far. It is worthy of a closer examination of the 
principles and algorithms as well as the performance of this method.  
4.3.1 Feasibility  
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INVDOCK is based on a ligand-protein inverse docking strategy such that a 
compound is attempted to dock to known ligand-binding pockets of each of the 
proteins in a protein 3D structural database. A protein is considered as a candidate 
potential target of a compound if that compound can be docked into the protein and 
the binding satisfies a molecular-mechanics based criterion for chemical 
complementarity [111]. Because of their capability in identifying potential ligands and 
binding conformations, docking algorithms are expected to be equally applicable to 
the inverse docking procedure for finding multiple protein targets to which a 
compound can bind or weakly bind [111,223]. 
The inverse docking algorithm requires a sufficient number of proteins of known 
3D structure to cover a diverse range of potential therapeutic effects. At present 
there are 19860 protein entries in the Protein Data Bank (PDB) and the number 
increases at a rate of well over 100 per month[319]. About 17% of these have 
unique sequence[320].  Introduction of high-throughput methods is expected to 
enable structural determination of 10,000 proteins with unique sequence within five 
years[29]. Thus the number of proteins is approaching a meaningful level to cover a 
diverse set of potential therapeutic targets.  
4.3.2 Algorithm 
The flowchart of the inverse docking algorithm is shown in Figure 4.1. A small 
molecule is attempted to dock to proteins with known 3D structures. By evaluating a 
molecular-mechanics based criterion for chemical complementarity, the docking 
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filter generate a putative protein / nucleotide targets list of the small molecule. This 
list is further filtered to find the putative therapeutic targets of that small molecule.  
 
To facilitate fast-speed search of potential protein targets of a chemical, a protein 
cavity database has been developed from the corresponding protein 3D structures 
in the PDB [111]. Each cavity entry is composed of a sphere cluster filling the cavity. 
Every cavity in each protein has a corresponding entry in this cavity database.  













a ligand to a cavity
Limited conformation
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Docking of a particular chemical to a cavity occurs by the following steps: First, 
the chemical is aligned within the selected site by matching the position of each 
atom of the compound with the center of spheres.  Because of the relatively 
low-resolution nature of the conformation sampling of the chemical, certain degree 
of structural clash is allowed at this stage. A molecular-mechanics conformation 
optimization is then conducted by a limited torsion space sampling of rotatable 
bonds in the chemical and those in the side-chain of the receptor amino acid 
residues at the binding site. Each rotatable bond is sampled in the range of ±15o. 
This is followed by 50 iterations of Cartesian coordinate energy minimization on all 
chemical and protein atoms at the binding site so as to further optimize the 
compound-protein complex. Energy minimization is by a steepest decent method.  
In both torsion optimization and energy minimization, AMBER force fields [120] 
are used for covalent bond, bond angle, torsion, and non-bonded Van der Waals 
and electrostatic interactions. The partial charges of drug atoms are assigned 
following the method described in [446]. Morse potential [321], which is a function of 
donor-acceptor distance, is used to represent hydrogen bond terms. This potential 
has been shown to give reasonable description of hydrogen bond energy and 
dynamics in biomolecules [322,323]. The energy function is: 

























































In this function, R , θ  and φ  denotes bond length, bond angle and torsion 
angle respectively, eqR , eqθ  and eqφ  are taken as equilibrium bond length, 
angle and torsion angle respectively and their values are from the original PDB 
structure and the structure of the drug respectively; Kr  and θK  are covalent 
and bond angle bending force constant respectively; nV  and n  are torsion 
parameters; r  is the hydrogen bond donor-acceptor distance, and 0V , a  and 
0r  are hydrogen bond potential parameters. 
Scoring of docked molecules is based on a ligand-protein interaction energy 
function LPE∆  composed of the same hydrogen bond and non-bonded terms as 
those used for structure optimization [111]. Analysis of a large number of PDB 
ligand-protein complexes shows that the computed LPE∆  is generally below 
NEThreshold α−=∆  kcal/mol, where N  is the number of ligand atoms and α  is a 
constant ~1.0 10. The exact value of α  can be determined by fitting the linear 
equation NEThreshold α−=∆  to the computed LPE∆  for a large set of PDB 
structures. This statistically derived energy value can be used empirically as a 
threshold for screening likely binders. A polynomial form of ThresholdE∆  involving 
more parameters may also be introduced to derive an energy threshold. LPE∆  can 
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be required to be lower than ThresholdE∆  when selecting successfully docked 
structures. A discussion on the typical binding energies can be found in [317]. 
Drug binding is competitive in nature. A drug is less likely to be effective if it binds 
to its receptor non-competitively against natural ligands and, to some extent, other 
drugs that bind to the same receptor site. This binding competitiveness may be 
partially taken into consideration for cavities known as ligand-bound in at least one 
PDB entry. Ligands in PDB structures are known binders. Therefore PDB ligands 
bound to the same receptor site as that of a docked molecule may thus be 
considered as “competitors” of that molecule. In INVDOCK selection of a putative 
protein target, the computed LPE∆  is not only evaluated against ThresholdE∆  but 
also compared to the ligand-protein interaction energy of the corresponding PDB 
ligands that bind in the same cavity in this or other relevant PDB entries. The 
Ligand-protein interaction energy for the relevant PDB structures is computed by the 
same energy functions as that for the docked molecule. In addition to the condition 
that it be lower than ThresholdE∆ , LPE∆  of a docked molecule is required to be lower 
than a “competitor” energy threshold CompetitorE∆  when selecting a putative target. 
CompetitorE∆  can be taken as highest ligand-protein interaction energy of the 
corresponding PDB ligands multiplied by a factor β .  In order to be able to find 
weak binders as well as strong binders, a factor 1≤β  is introduced to scale the 
ligand-protein interaction energy of PDB ligands. This is because a weak binder may 
have slightly higher interaction energy than that of a PDB binder. No experimental 
data has been found to determine the value of β . Hence β  has been tentatively 
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determined by an analysis of the computed energy for a number of compounds. A 
value of 0.8 has been suggested for β  which leads to reasonable results 
statistically [111]. 
4.3.3 Validation studies on synthetic chemicals 
The effectiveness of INVDOCK prediction of the protein targets of synthetic 
chemicals can be demonstrated from a recent study on a number of clinical agents 
[111]. The results of one drug, tamoxifen (Figure 3.1), are quoted here. Tamoxifen is 
an anticancer drug widely used for treatment of breast cancer [324] and it has been 
approved as the first cancer preventive drug. Tamoxifen metabolite 4H-tamoxifen is 
believed to be the major contributor to the anti-oestrogenic effects of tamoxifen 
inside the human body [324].  
 
Potential human and mammalian protein targets of 4H-tamoxifen identified by 
INVDOCK are given in Table 4.1 along with the respective clinical implications from 
experiments. The computed binding energies are not listed as energy alone may not 
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be a good indicator on the strength of drug binding in-vivo because of the compitions 
from other natural ligands. A number of known protein targets of tamoxifen are found 
in the Table. These include estrogen receptor [324], protein kinase C [325], 
collagenase [326], hydroxysteroid dehydrogenase [327], Alcohol dehydrogenase 
[328], and prostaglandin synthetase [329]. It has been observed that two other 
INVDOCK identified proteins glutathione transferase and 3-alpha-hydroxysteroid 
dehydrogenase exhibited altered activity by tamoxifen [330,331], which may be 
indicative of direct binding of tamoxifen to these proteins. Experiments showed that 
the levels of another two identified proteins, dihydrofolate reductase and 
immunoglobulin, are changed by tamoxifen [332,333]. Ligand binding is known to 
self-regulate protein levels in certain cases [334]. It remains to be seen whether 
these two proteins are also the targets of tamoxifen as implicated by INVDOCK 
search.  
 
Table 4.1: Potential therapeutic targets of 4H-tamoxifen identified from INVDOCK 




Target Name Experimental Findings Therapeutic Implications
1a52 Estrogen Receptor Drug target [324] Breast cancer [324] 





Inhibited activity [327] 
 
Tumor cell invasion and 
cancer metastasis [327] 
1az1 Aldose Reductase  Diabetes 
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1bnt Carbonic Anhydrase   
1boz Dihydrofolate Reductase Decreased level [332] Combination therapy for 
cancer[332] 




1dda Alcohol dehydrogenase Inhibition [328] Enhanced ethanol's 






















Temporarily enhanced Ig 
level [333] 







1ulb Purine Nucleoside 
Phosphorylase 
  
1zqf DNA Polymerase  Viral infection 
2nll Retinoic Acid Receptor   
1a25 Protein Kinase C Inhibition [325] Cancer [325] 





Effect on androgen induced 
activity [331] 
Hepatic steroid metabolism 
[331] 
1pth Prostaglandin H2 
Synthase-1 
Direct inhibition [329] Prevention of 
vasoconstriction [329] 
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1sep Sepiapterin Reductase   
2toh Tyrosine 3-Monooxygenase   
 
It is noted that a known target of tamoxifen such as calmodulin [325] is not 
identified by INVDOCK. One possible reason might be that the available PDB 
structures of calmodulin are not sufficiently close to the tamoxifen-bound 
conformation. None of these PDB structures is bound by a ligand similar in structure 
to tamoxifen. The conformation of calmodulin is known to change significantly by 
binding of ligands [335]. Because of the intrinsic flexibility of this protein, it is highly 
likely that ligand binding to this protein involves induced-fit. The analysis of two PDB 
structures of calmodulin bound by a different ligand (PDB id: 1a29 and 2bbm) shows 
that the conformation of this protein is dependent on its binding ligand. In a recent 
molecular docking study, a ligand was docked into calmodulin by the consideration 
of conformation changes that mimic an induced fit [336]. It is also found that 
4H-tamoxifen can be placed into calmodulin with slightly less favorable steric 
interaction than allowed by the INVDOCK scoring function. An appropriate 
conformation change in calmodulin might allow for the removal of this un-favorable 
interaction.  
The limited number of protein entries available in the cavity database is also 
expected to result in missed hits. For instance, known tamoxifen metabolizing 
protein cytochrome P450 [337] is not identified in this work because no 
corresponding human or mammalian entry is available in the cavity database. A 
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search of bacterial proteins in the database identified this protein (PDB Id: 5cp4 and 
1cpt) as a putative target. 
As shown in Table 4.1, apart from the ten putative protein targets that have been 
implicated or confirmed experimentally, INVDOCK identified ten other proteins as 
putative targets of 4H-tamoxifen. These include aldose reductase, Arginase, 
carbonic anhydrase, macrophage migration inhibitory factor, purine nucleoside 
phosphorylase, DNA polymerase, hypoxanthine-guanine phosphoribosyltransferase, 
retinoic acid oxidase, sepiapterin reductase, and tyrosine 3-monooxygenase. No 
literature has been found to link tamoxifen to each of these proteins. There is also no 
report that indicates each of these proteins is not a target of tamoxifen or its analogs. 
Further investigation is therefore needed to determine whether or not 4H-tamoxifen 
can bind to these proteins. 
In summary, the majority of INVDOCK identified protein targets have been 
implicated or confirmed by experiments [111,223]. Ligand-protein inverse docking 
appears to be a useful approach for computer-aided identification of potential protein 
targets of small synthetic molecules. The ability of identification of therapeutic 
targets of MP ingredients is evaluated as follows. 
 
4.4 In silico prediction of therapeutic targets of MP ingredients 
In this work, the therapeutic targets of six MP ingredients have been predicted by 
the in silico method INVDOCK. The results, together with the those of three other 
MP ingredients published before, have been compared with available experimental 
findings [338]. These nine ingredients were selected based on a comprehensive 
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MEDLINE [339] search on MP related publications, and those ingredients with 
relatively abundant amount of references are selected. This is to ensure that, for 
each selected ingredient, there is a reasonable amount of experimental findings to 
make a sensible evaluation of INVDOCK results.  
The nine MP ingredients include genistein, ginsenoside Rg1, quercetin, 
acronycine, baicalin, emodin, allicin, catechin and camptothecin. These compounds 
have been subjects of various investigations including the probing of their molecular 
targets. The availability of relevant experimental findings makes it possible to 
conduct comparative study and to evaluate INVDOCK derived results. The 3D 
structures of each of these MP ingredients are generated by the following procedure: 
The 2D structure of each MP ingredient is obtained from the CCD database 
(http://www.chemnetbase.com/) and it is then converted into 3D structure using 
CONCORD (http://www.tripos.com/admin/LitCtr/concord.pdf) licensed from SYBYL.  
All the proteins with known 3D structure in the Protein Databank PDB are 
searched by INVDOCK for identification of potential protein targets of the MP 
ingredients. The therapeutic target database was then searched to provide a list of 
candidate therapeutic targets from the complete protein targets list. 
To evaluate the usefulness of INVDOCK for predicting the therapeutic targets of 
the selected MP ingredients, literature have been searched for reports about the 
experimentally determined targets of these MP ingredients. It is noted that a 
substantial number of experimental binding studies have been conducted at 
micro-mole level which is significantly higher then that of average in vivo drug 
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concentration. Although binding analysis at higher concentrations has routinely been 
used as an indication about in vivo effect at lower concentrations [340,341], certain 
caution is needed for searching related experimental reports. Two additional 
requirements have been used in the selection of related experimental reports. One 
is that a reported experiment be conducted at concentrations no higher than the 
routinely used ones[340,342]. Another is that the physiological effect of the reported 
binding has been observed. 
Pharmacokinetics is another factor that needs to be considered when searching 
for related experimental reports. While some reports may indicate the binding of a 
selected MP ingredient with a protein, it may not be clear whether that particular MP 
ingredient can reach the target site with sufficient concentration. Therefore, 
additional experimental evidence such as the reported in vivo effects of the 
particular MP ingredient on the specific organ have been used as an indication that 
the MP ingredient likely reach a particular site at certain level of concentration.  
4.4.1 Genistein 
Genistein (Figure 4.3) is a soy-derived isoflavone of therapeutic interest. Dietary 
intake of soy is associated with a decreased risk of both hormone-dependent and 
hormone-independent cancers [343]. At the molecular level, genistein inhibits the 
activity of ATP binding enzymes such as tyrosine-specific protein kinase, 
topoisomerase II and enzymes involved in phosphatidylinositol turnover. Moreover, 
genistein can act via an estrogen receptor-meditated mechanism [344]. At the 
cellular level, genistein induces apoptosis and differentiation in cancer cells, inhibits 
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cell proliferation, modulates cell cycling, exerts antioxidant effects, inhibits 
angiogenisis, and suppresses osteoclast and lymphocyte functions [344]. In addition, 
it acts as an immunosuppressant and shows beneficial effects in the treatment of 
osteoporosis, cardiovascular disease, and menopause [344]. 
The pharmacokinetics profile of genistein has been well studied. One experiment 
on an animal model showed a favorable uptake of genistein [345]. In another study, 
genistein has been found in various organs of rats, including gut, excretory organs, 
respiratory organs, peripheral organs, reproductive organs. The pharmacokinetics 
data were also measured [346]. The good pharmacokinetic profile of genistein also 
contributes to its wide range of beneficial effects. 
 
INVDOCK identifies 18 potential therapeutic targets of genistein, which are listed 
in Table 4.2 together with available experimental findings. Two of these proteins 
have been reported to be directly inhibited by genistein in vitro. These targets are 
estrogen receptor [347], and FGF receptor 1 [348]. Estrogen receptor beta is 
reported to bind genistein with an affinity close to that of 17beta-estradiol. However, 
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it remains to be determined whether it is a mediator of genistein's activity in vivo. 
FGF receptor 1 is a kind of tyrosine kinase. As a general tyrosine kinase inhibitor, 
genistein is expected to inhibit FGF receptor 1. These two proteins are known 
anti-cancer targets and there is indeed a report about the effect of genistein on 
cancer. [349]  
 
Table 4.2: Potential therapeutic targets of Genistein identified from INVDOCK search 




Target Name Experimental Findings Therapeutic 
Implications 
1a35 Topoisomerase I Genistein has anti- 
topoisomerase I effect 
[350]. 
Cancer [349] 
1a7c Plasminogen activator 
inhibitor 
Genistein shifts urokinase 




1akf Estrogen receptor Genistein binds to 









activates HPRT [354]. 
Malaria [355] 
1di8 Cyclin-dependent kinase 2 Genistein suppresses 
CDK2 activity [356]. 
Cardiovascular 
disease [353] 
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1fgi FGF receptor 1 Genistein blocks 
cytoplasmic receptor 
domain [348]. 
Cancer [349] , 
Angiogenesis [353] 
1rts Thymidylate synthetase      Cancer [349] 
1ula Purine nucleoside 
phosphorylase 
 Cancer [349], Malaria 
[355] 
2dhf Dihydrofolate reductase  Leprosy [357] 
1vbt Cyclophilin A  Cancer [349], 
1db4 Phospholipase A2  Inflammation [358] 
1diy Prostaglandin H2 synthase Genistein decreased the 
specific activity of 
prostaglandin H2 
synthase prepared from 
A431 cells. [359] 
Inflammation [358] 
1d8d Farnesyltransferase  Cancer [349] 
1bpx DNA polymerase  Viral infection [360] 
1b3o Inosine dehydrogenase  Malaria [355] 
1azm Carbonic anhydrase I  Hypertension, 
Glaucoma[361], 
Cancer [349] 
1awn Guanylyl cyclase  Cancer [349] 
1a25 Protein kinase C  Cardiovascular 
disease [353]  
Cancer [349] 
 
Experiments also showed that the activity or expression level of each of the five 
INVDOCK identified therapeutic targets given below is affected by genistein. Ligand 
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binding may influence the activity of a protein, and it is also known to self-regulate 
protein levels in certain cases [334]. Hence there is a possibility that these observed 
phenomena indicate genistein’s binding to each of these proteins as predicted by 
INVDOCK. The activities of cyclin-dependent kinase 2 [356], topoisomerase I [350] 
and prostaglandin H2 synthase[359] have been reported to be suppressed by 
genistein. Cyclin-dependent kinase 2 is a therapeutic target for cardiovascular 
disease. Genistein has been found to possess an effect preventive of cardiovascular 
disease [362]. Topoisomerase I is another therapeutic target of cancer. 
Prostaglandin H2 synthase (COX) is a major therapeutic target for inflammation. 
Genistein has been reported to have some relationship with inflammation [358]. Also, 
genistein has been known to induce a shift towards antiproteolysis on 
urokinase/plasminogen activator inhibitor proteolytic balances [351], which seems to 
suggest that this protein is a target and it may also account for genistein’ efficacy in 
cancer therapy. Genistein can marginally induce hypoxanthine-guanine 
phosphoribosyltransferase [354], which seems to suggest a mechanism of genistein 
effect in treating malaria [355].  
Moreover, there are 11 identified therapeutic targets without experimental 
validation or invalidation. Further experimental investigation is needed to determine 
whether each of these proteins is a target of genistein as predicted by INVDOCK. 
These targets have been explored in treatments of eight different diseases. Among 
them, the effect of genistein on cancer[349], malaria[355], leprosy[357], 
inflammation[358], herpes viral infection[360], glaucoma[361] and vascular 
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disease[353] has been reported in cell cultivation or animal models. However, 
whether these effects are due to the predicted interaction of genistein with some of 
these proteins remain to be studied. Moreover the pharmacokinetic profile of 
genistein needs also to be studied to assess the clinical effect of genistein on these 
diseases. 
4.4.2 Ginsenoside Rg1  
Ginsenoside Rg1 (Figure 4.4) is a major bioactive component of ginseng. 
Ginseng is a highly valued MP in the Far East and has gained popularity in the West 
during the last decade [363]. It can be used to combat stress, to enhance both the 
central and immune systems, and to help maintaining optimal oxidative status 
against certain chronic disease states and aging[364]. It is also reported to have an 
effect to prevent cancer[365]. The pharmacokinetic data of ginsenoside Rg1 is not 
so well studied as genistein. The available data showed that ginsenoside Rg1 had a 
wide distribution and long half-life in the body [366,367].  
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The predicted therapeutic targets of ginsenoside Rg1 are given in Table 4.3. 
Three proteins are identified as potential therapeutic targets of this MP ingredient. 
One is endothelial nitric-oxide synthase, which is known to be inhibited by 
ginsenoside Rg1[368] and this inhibition may contribute to the observed 
maintenance of optimal oxidative status against chronic disease states and 
aging[364]. DNA polymerase beta has not been reported to bind ginsenoside Rg1, 
however, it has been found that ginsenoside Rg1 can stimulate DNA synthesis[369] 
and activate DNA polymerase delta[370]. Protein cyclophilin is also identified as a 
potential target by INVDOCK, while no experimental reports are available to confirm 
or invalidate it. This protein is related to immunomodulatory activity, which is one of 
the well-known therapeutic effects of ginsenosides including ginsenoside Rg1[371]. 
In addition to these therapeutic targets, INVDOCK also predicted an experimentally 
confirmed non-therapeutic target, 1,4-galactosyltransferase, an in vivo metabolizing 
enzyme of ginsenoside Rg1 [372].  
 
Table 4.3: Potential therapeutic targets of ginsenoside Rg1 identified from INVDOCK 


















Viral infection (herpes) 
[373] 
1rmh Cyclophilin A  Immune response [371] 
3nos Endothelial nitric-oxide 
synthase 
Rg1 inhibits NOS dose 
dependently [368]. 
Maintaining optimal 
oxidative status [364] 
 
4.4.3 Quercetin 
Quercetin (Figure 4.5) is a flavonoid nearly ubiquitous in plants and it is 
particularly rich in seeds, citrus fruits, olive oil, tea, and red wine [374]. Certain plants 
containing flavonoids have been used in traditional medicines and there have been 
suggestions for exploring these MPs therapeutically [374]. Quercetin is one of the 
most comprehensively studied flavonoids which are suitable for evaluation of 
INVDOCK. However, unfortunately, in vivo data on the disposition, absorption, 
bioavailability, and metabolism of quercetin after intravenous and oral administration 
in humans are scarce and contradictory [375]. One study on rat showed that 
quercetin, but not its glycosides, is absorbed from the rat stomach [376]. Another 
study suggests that quercetin 3-O-beta-glucoside was hydrolysed before or during 
its intestinal absorption [377]. Also, quercetin and rutin were found in plasma as 
glucuronides and/or sulfates of quercetin and as unconjugated quercetin aglycone 
[378]. 




Eleven therapeutic targets are identified from INVDOCK computation. The 
results are shown in Table 4.4. Three of them are reported to be inhibited by 
quercetin directly. They are estrogen receptor, phospholipase A2 and SRC tyrosine 
kinase[374,379]. SRC tyrosine kinase and estrogen receptor are established 
therapeutic targets for cancer, which is consistent with the well known anti-cancer 
effect of quercetin [380]. SRC tyrosine kinase is also a therapeutic target for 
osteoporosis. Studies on quercetin and its derivatives showed they have beneficial 
effect on this disease in an animal model [381]. Estrogen receptor has also been 
explored as a therapeutic target for vascular disease. The efficacy of quercetin in 
vascular diseases has been well observed [382].  
 
Table 4.4: Potential therapeutic targets of quercetin identified from INVDOCK search 
of human and mammalian proteins. 
 
PDB ID Target Name Experimental Findings Therapeutic 
Implications 
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1a35 DNA topoisomerase I Quercetin inhibits 
topoisomerase I - catalyzed 
DNA religation [383] 
Cancer [380] 
1akf Estrogen receptor Quercetin binds to type II 




1azm Carbonic anhydrase I  Glaucoma, 
Hypertension [384], 
Cancer [380] 
1bpx DNA polymerase Quercetin and myricetin 
exhibited complex interaction 
with DNA polymerases [374]. 
Herpes viral infection 
[385],[382] 
1bvm Phospholipase A2 Inhibited by quercetin [374]. Inflammation [386] 
[382] 












Malaria [388]  
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1fmk SRC tyrosine kinase  Inhibited by quercetin [374]. Cancer [380] 
Osteoporosis [381] 
 
Quercetin has also been reported to inhibit the topoisomerase I catalyzed DNA 
religation [383], inhibit the phosphorylating activity of protein kinase C [374], as well 
as exhibit complex interaction with DNA polymerase [374]. These proteins are also 
identified as potential targets of quercetin by INVDOCK. Therapeutically, they are 
used in the treatment of cancer, vascular diseases, and viral infection respectively. 
The uses of quercetin in these diseases are also reported [380,382].   
There are 5 other INDOCK predicted therapeutic targets without available 
experimental finding to either verify or invalidate them. Quercetin is known to induce 
HGPRT-deficient mutants in rats [389], which might result from the interaction 
between this protein and quercetin. HGPRT is a therapeutic target for the treatment 
of malaria. Another therapeutic target for malaria, dihydroorotate dehydrogenase, is 
also identified as potential target of quercetin. It is noted that experiment has shown 
that quercetin gave strong antimalarial activity [388]. Other yet-to-be-verified 
potential targets include chymase, cathepsin B and carbonic anhydrase I. They are 
therapeutic targets for 9 diseases. Among them the effect of quercetin on 
hypertension [384], cancer [380], autoimmune diseases [387], asthma [390], 
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cardiovascular diseases [382], inflammation [382] and dermatitis [391] has been 
reported in animal models or clinical trials.  
A number of targets of quercetin unrelated to therapeutics have been reported 
[374]. The 3D structures of most of these proteins are unavailable and thus beyond 
the reach of INVDOCK. Nonetheless, the 3D structures of four of these proteins are 
available. Two of these proteins are identified by INVDOCK as potential targets. 
They are ribonuclease and nitric oxide synthase. The other two reported targets, 
aldose reductase and amylase, are missed by INVDOCK. Quercetin has also been 
reported as a competitor for ATP and GTP in vivo[374]. Therefore it is not surprising 
that quercetin can bind to some of the ATP-binding or GTP-binding enzymes. 
INVDOCK identifies two such enzymes as potential targets, which include 
adenosine kinse and guanylyl cyclase.  
4.4.4 Acronycine 
Acronycine (Figure 4.6) is an active compound from Acronychia pedunculata. It 
is reported to have anti-cancer effects [392]. Crassum intestine 38 adenocarcinoma 
cell growth and L1210 leukemia cell growth are reported to be inhibited by this 
compound through a mechanism of inhibition the synthesis of DNA or RNA [393]. 
Acronycine is a lipophilic alkaloid. Its etoposide solution was active in 
multidrug-resistant Chinese hamster ovary cells. The oral bioavailability of an 
acronycine solution in etoposide diluent was only 50% but both i.p. and p.o. 
regimens achieved plasma levels greater than 1.0 micrograms/ml. [394]. 




As shown in Table 4.5, INVDOCK finds three potential therapeutic molecular 
targets for acronycine. Among them, DNA polymerase is experimentally reported to 
be a target responsible for its anti-cancer effect [392]. The other two are neither 
confirmed nor invalidated by experiments. They are beta-catenin, a potential 
anticancer target, and aldose reductase, a target for diabetes. Further experimental 
study is needed to clarify whether or not these are targets of acronycine. 
 
Table 4.5: Potential therapeutic targets of acronycine identified from INVDOCK 




Target Name Experimental 
Findings 
Therapeutic Implications 
2acq Aldose reductase  Diabetes 
3bct Beta-catenin  Cancer [392] 














Baicalin (Figure 4.7) is an active compound from Scutellaria baicalensis or 
Oroxylum indicum. It is reported to have anti-cancer [395], anti-inflammation [396], 
anti-AIDS effects [397], and has been used in the treatment of diabetes [398] and 
liver problems [399]. Baicalin is absorbed from the rat gastrointestinal tract as the 
aglycone and restored to its original form [400]. One study showed that its plasma 
concentration reached a peak of 0.42 microgram/mL 5.3 h after oral administration, 
600 mg/kg [401].  
As shown in Table 4.6, INVDOCK finds 9 potential therapeutic protein targets for 
baicalin. Two of these targets were inhibited by baicalin. One is DNA polymerase 
beta, an anti-virus target, which could be weakly inhibited by baicalin [402]. The 
other is aldose reductase [399], a target for the treatment of diabetes [398]. It has 
been reported that baicalin has certain effects on two other therapeutic targets 
suggested by INVDOCK. Baicalin has been found to down-regulate the expression 
level of cyclin-dependent kinase 2 [403], which are known anti-cancer targets. This 









HO OH  
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compound has also been reported to have an inhibitory effect on phospholipase A2 
[404,405], which is a known anti-inflammatory target. The anti-cancer and 
anti-inflammatory effects of binding of baicalin to these implicated targets have been 
observed experimentally [395,396]. The other 5 predicted targets are neither 
confirmed nor invalidated by experiments. They are all potential anti-cancer targets. 
Among them, protein kinase C and adenylyl cyclase are also reported to be 
therapeutic targets in vascular diseases. Baicalin was observed to have an effect on 
the contractility of rat isolated mesenteric arteries[406].  Further study is needed to 
determine whether these are targets of baicalin. 
 
Table 4.6: Potential therapeutic targets of baicalin identified from INVDOCK search 




Target Name Experimental Findings Therapeutic 
Implications 
121p H-Ras p21 protein  Cancer [395] 
1ads Aldose reductase Baicalin reduced RBC sorbitol 
levels in diabetic rats as 
inhibitor of Aldose 
Reductase.[399] 
Diabetes [398] 
1agw FGF receptor 1  Cancer [395] 
1a25 Protein kinase C  Vascular disease[406]， 
Cancer [395] 
1awk Adenylyl cyclase  Vascular disease [406],  
Heart failure, Erectile 
dysfunction 
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1awn Guanylyl cyclase  Cancer [395] 
1irb 
 
Phospholipase A2  Inhibition effect. [404,405] Inflammation [396] 











 Emodin (Figure 4.8) is an active compound from Rheum palmatum, Rumex 
dentatus and Cassiatora. It has been found to have anti-cancer [407], 
immuno-modulation [408] and laxative effects. Administration of emodin to rabbits by 
i.v. bolus resulted in a serum profile which could be well described by a 
two-compartment model. Oral administration of emodin resulted in a very low serum 
concentration but protein binding assays show that emodin was highly bound to 
serum protein [409].Liver, kidney and intestinal tract showed higher concentrations 
than plasma [410]. 
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As shown in Table 4.7, INVDOCK identifies five potential therapeutic protein 
targets for emodin. Two of them have relevant publications, which are protein kinase 
C [411], and nuclear factor Kappa-B [412]. Emodin was reported to inhibit protein 
kinase C[411]. Protein kinase C has been explored as a therapeutic target in cancer 
and vascular diseases. Emodin’s beneficial effect in cancer were observed in mice 
[407]. Emodin was reported to inhibit TNF-induced NF-kappaB activation [412]. 
NF-kappaB played an important role in a number of diseases. Among them, 
emodin’s beneficial effects in inflammation [413] and atherosclerosis[414] were 
reported. The other three targets are neither confirmed nor invalidated by 
experiments. They are therapeutic targets for cancer [407], inflammation [413] and 
diabetes. It remains to be seen whether or not these are targets of emodin as 
predicted by INVDOCK. 
 
Table 4.7: Potential therapeutic targets of emodin identified from INVDOCK search of 




Target Name Experimental 
Findings 
Therapeutic Implications 
2acq Aldose reductase  Diabetic treatment 
1pth Prostaglandin H2 
Synthase-1 
 Inflammation [413] 
3bct Beta-catenin  Cancer [407] 
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1a25 Protein kinase C Inhibitor[411] Cancer [407], Vascular disease 
 
4.4.7 Allicin 
Allicin (Figure 4.9) is a bioactive compound from garlic with a number of 
therapeutic effects. It is known to reduce blood cholesterol, triglycerides levels and 
systolic blood pressure in hypercholesterolemic rats [415]. This compound has been 
shown to possess antimicrobial activities [416] especially against H. pylori [417]. It 
selectively inhibits the GSH-dependent PGH2 to PGE2 isomerase in 
adenocarcinoma cell line, which has implication in pulmonary vasodilating, 
anti-inflammatory as well as anti-cancer effects [418].  It has also been found to be 
an antioxidant agent [419].  
 
 Putative human and mammalian therapeutic protein targets of allicin identified 
by INVDOCK are given in Table 4.8 along with the respective clinical implications 
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from experiments. Four putative protein targets are identified. One of them, insulin, 
seems to be implicated by experiment. It has been observed that the level of insulin 
is increased by allicin [420].  
 
Table 4.8: Potential therapeutic targets of allicin identified from INVDOCK 










Insulin Increased insulin 
level [420]  
Diabetes [420] 
1ah3 Aldose Reductase  Diabetes 





Prostatic Acid Phosphatase  Cancer (prostate cancer) 
 
INVDOCK also finds aldose reductase, CAMP-dependent protein kinase, and 
prostatic acid phosphatase as putative therapeutic targets. However there is no 
experimental study to either implicate or invalidate each of these targets. Interaction 
of allicin with insulin as well as aldose reductase has implications for diabetes, which 
is consistent with the observed effect of allicin on diabetes [421]. CAMP-dependent 
protein kinase and prostatic acid phosphatase have implications in anticancer 
effects, which is consistent with observed anticancer effects of garlic [422]. Further 
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experimental investigation is needed to test whether these three proteins are targets 
of allicin. 
4.4.8 Catechin 
Catechin (Figure 4.10), also known as cyanidol, is an active compound from 
green tea. It has been shown to inhibit the growth of human breast cancer cells [423] 
and prostate cancer cells [424] partly because of its inhibition of cyclin-dependent 
kinases [425]). The antitumor activity of this compound may also arise from its 
inhibition of tyrosine phosphorylation of PDGF beta-receptor [426], induction of 
apoptosis [427] and inhibition of matrix metalloproteinases [428]. Catechin exhibits 
anti-inflammatory as well as cancer chemopreventive effects in many animal tumor 
bioassays, cell culture systems, and epidemiological studies [429]. Some of these 
effects of catechin are in part from its inhibition of TNF-alpha and NF-kappaB. This 
compound also has antiplaque and hepatoprotective effects via reduction of 
membrane fluidity [430]. It has been reported that this compound has antioxidative 
action mediated by the activation of glutathione peroxidase [431].  
INVDOCK search produces seventeen putative therapeutic targets, which are 
given in Table 4.9. Seven of these targets have been confirmed by experiments, 
which showed that catechin inhibits each of them. These include cyclin-dependent 
kinase and FGF receptor [425], neutrophil collagenase [428], protein kinase C [425], 
CAMP-dependent protein kinase [432] TNF-alpha and NF-kappaB p65 [429]. 
Inhibition of each of the first five proteins has potential anticancer implications, 
binding to the sixth protein may produce anti-inflammatory effects, and the 
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interaction with the seventh and eighth proteins may lead to anti-inflammatory as 
well as cancer chemopreventive effects.  
 
Table 4.9: Potential therapeutic targets of catechin identified from INVDOCK search 




Target Name Experimental Findings Therapeutic 
Implications 
1ads Aldose Reductase  Diabetes 
1agw FGF Receptor 1 Inhibitor[433] Cancer[433]  
1aqc X11  Anti-clotting 
1crp 
 







Immunoenhancing effect on 





Neutrophil Collagenase Collagenase inhibitor [428] Cancer [428] 
1a25 Protein Kinase C Inhibitory effect [436] Cancer [436],  Vascular 
disease 
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Inhibitor [432] Cancer [432] 
1p38 
 
MAP kinase p38 Inhibition of activation of 
p38 mitogen activated 
protein kinase. 
Cancer 
1rpa Prostatic acid 
phosphatase 
 Cancer (prostate cancer) 
1wav 
 






1cpj Cathepsin B Activator [429] Cancer [429]  
1jsu Cyclin-dependent 
kinase-2 
Inhibitor [433] Cancer [433] 
1ram Transcription factor NF- 
KB p65 
Inhibitor [429] Inflammation [429] 
2tnf Tumor necrosis factor 
alpha 
Inhibitor [429] Inflammation [429] 
 
Available experimental data also seem to implicate another five of INVDOCK 
identified therapeutic targets. Catechin has been found to be an activator of 
cathepsin B and insulin [429]. It is possible that activation of each protein is by direct 
binding of catechin. Activation of cathepsin may produce anticancer effects, while 
activation of insulin may help reduce glucose levels and thus have implications in 
diabetes treatment. Catechin is known to inhibit both the ras-transformed cells  and 
the activation of p38 mitogen-activated protein kinase [434], which may have 
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implication in anticancer properties. One possible reason for these inhibitory effects 
are due to the binding of catechin to ras p21 protein and MAP kinase p38 
respectively as predicted by INVDOCK. Catechin is also known to have 
immuno-enhancing effect on T and B cell functions [435], which may also result from 
binding of catechin to immunoglobulin lambda light chain as predicted by INVDOCK. 
Further investigation is needed to determine whether these proteins are targets of 
catechin. 
Moreover, INVDOCK identified four additional putative therapeutic targets. 
These are aldose reductase, X11, guanylyl cyclase, and C-AMP-dependent protein 
kinase. No experimental information has been found to either implicate or invalidate 
them. Hence, further study is needed to determine whether these proteins are 
targets of catechin. The potential therapeutic effect of the binding of catechin to each 
of these proteins is diabetes treatment for the aldose reductase, anti-clotting for X11, 
and anticancer for guanylyl cyclase and C-AMP-dependent protein kinase 
respectively.  
Some known therapeutic targets of catechin are not found by INVDOCK search. 
These include matrix metalloproteinase-2, matrix metalloproteinase-9, matrix 
metalloproteinase-12 and glutathione peroxidase. This occurs because of a lack of 
relevant structures in the database. The cavity database does not yet have 3D 
structures of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix 
metalloproteinase-12. Although the 3D structures of glutathione peroxidase are 
available in the database, these are ligand-free structures that may not be a suitable 
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system for accurate analysis of the binding of a compound that affects the function 
of that protein. Thus these structures are not used in INVDOCK study. 
4.4.9 Camptothecin 
Camptothecin (Figure 4.11) is a compound from the plant Canptotheca 
acuninata. It has well recognized antitumour activities and has been evaluated in 
clinical trials [437]. 
 
As shown in Table 4.10, INVDOCK identifies nine putative therapeutic protein 
targets, eight of which has anticancer implication. Two such putative targets have 
been confirmed experimentally. These are topoisomerase I [438] and protein kinase 
C [439,440]. Another identified putative target is implicated by experiment. It has 
been shown that camptothecin inhibits the activity of calpain [441], which may be 
indicative of direct binding of camptothecin to this protein. Such a binding is 
expected to induce apoptosis in leukemic cells.  
 
Table 4.10: Potential therapeutic targets of camptothecin identified from INVDOCK 
search of human and mammalian proteins. 
  



























1a25 Protein Kinase C Inhibitor [440] 
 






3bct Beta-Catenin  Cancer 








Caused elevation of PTPase 
in the cytosol and the nucleus 
which play a critical role in the 
induction of the differentiation 
of IW32 erythroleukemia cells.  
[443] 
Cancer [443] 
1a35 Topoisomerase I Inhibitor [438] Cancer [438] 
 
Two additional putative targets seem to be implicated by experiments as well. 
Camptothecin has been found to elevate the level of protein tyrosine phosphatase 
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[443] and to increase intracellular glutathione [442], which might result from its 
binding to receptor protein tyrosine phosphatase and glutathione S-transferase 
respectively as predicted by INVDOCK. Binding to these two proteins may have 
anticancer implication. For instance, it has been found that camptothecin causes 
elevation of PTPase in the cytosol and the nucleus, which affects the induction of the 
differentiation of IW32 erythroleukemia cells. Therefore INVDOCK prediction of 
these two putative targets may partly explain the observed anticancer activities of 
camptothecin.  
Other identified potential therapeutic targets are DNA polymerase beta, 
CAMP-dependent protein kinase, beta-catenin and aldose reductase. There is no 
experimental information to either implicate or invalidate these targets. Further study 
is therefore needed to clarify this. Anticancer activity may potentially be produced by 
camptothecin binding to DNA polymerase beta, CAMP-dependent protein kinase 
and beta-catenin respectively. The effect of camptothecin on aldose reductase may 
have implication in diabetes treatment. 
 
4.5 Limitations and suggested improvement of INVDOCK 
 Table 4.11 summarizes the comparison between INVDOCK predictions and 
available experimental findings for the nine MP ingredients presented here. Overall 
about 51% of INVDOCK identified potential therapeutic targets of these MP 
ingredients have relevant experimental findings. Moreover, about 70% of the 
identified therapeutic implications related to these targets have been reported to 
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occur in cultivated cells, animal models or clinical trails. It seems that INVDOCK is 
capable of providing useful information for experimental researchers in probing the 
mechanisms of MPs. 
 
Table 4.11: Statistics of therapeutic targets of selected bioactive MP ingredients 
identified by INVDOCK search. The statistics of experimentally reported or 
implicated targets is also given for comparison. 
 


























Genistein 18 7 9 8 
Ginsenoside Rg1 3 2 3 3 
Quercetin 11 6 12 10 
Acronycine 3 1 4 2 
Baicalin 9 4 7 5 
Emodin 5 2 11 4 
Allicin 4 1 2 1 
Catechin 17 12 5 4 
Camptothecine 9 5 3 2 
Total 79 40 56 39 
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Discrepancy between INVDOCK results and available experimental data arises 
from a number of reasons. It is not expected that exhaustive experiments have been 
done to determine all protein targets of the studied MP ingredients. The lack of 
sufficient experimental data is likely an important factor for the discrepancy. Lack of 
relevant protein structures is likely to be another factor. 3D structure of a large 
number of known therapeutic targets is not available. Some of the 3D structures may 
be of little relevance here. These include entries containing incomplete sections or 
chains, protein mutants that are structurally different from the corresponding proteins 
investigated in experiments, ligand-bound proteins whose conformations are 
relevant only to a specific set of compounds, and macromolecular complexes 
unrelated to a particular biological process studied experimentally. “False hits” may 
thus be generated if these irrelevant structures are selected by INVDOCK. 
Anticipated rapid progress in structural genomics[320] is expected to provide a more 
diverse set of relevant structures. Knowledge from study of protein functions also 
facilitates the selection of relevant structures in determination of potential protein 
targets related to a particular cellular or physiological condition. 
As in other docking studies, INVDOCK does not take protein profiles, such as 
gene expression pattern and protein levels, into consideration, which may also be a 
source of discrepancy between INVDOCK computation and experiments. Some 
experimental studies of MP ingredients are based on the investigation of cell lines or 
other assays. Observation of molecular events related to the interaction with a 
particular protein requires that the protein be expressed at a sufficient level in the 
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system being investigated. If such a level is not reached at a particular setting, the 
corresponding experiment is not useful in probing the binding of a compound to that 
protein. Proteins not expressed or at too low levels are unlikely to be a detectable 
target. Advance in proteomics is providing rapidly growing information about the 
profiles of proteins inside cells[223]. Incorporation of this information into the 
INVDOCK procedure may be helpful in improving the prediction accuracy. 
Therapeutic action of a chemical requires it to achieve an adequate 
concentration in the body fluid bathing the target tissue. The concentration of a 
chemical is determined by its pharmacokinetic profile. Also these chemicals might 
undergo some extent of metabolism. In some cases, both the original chemical and 
the metabolited derivative could have the same effect through the same mechanism 
(e.g. Tamoxifen and 4-H-tamoxifen are both anti-cancer agents). However, in some 
cases, the metabolited derivative would lose its activity (e.g. quercetin gave strong 
antimalarial activity, however, its glucosides, showed little significant activity [388]). 
Therefore the ADME profile, which has been neglected in INVDOCK and other 
docking studies, needs to be considered. Rapid progress in our understanding of 




 A number of in silico methods for target identification are being explored or under 
consideration. Several methods have potential applications in facilitating the 
identification of therapeutic targets of MP ingredients. These include high-throughput 
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assay based approaches, extended QSAR approaches, statistical learning methods 
and extended docking methods. One of these methods, INVDOCK, has been 
specifically used in the identification of protein targets of MP ingredients as well as 
synthetic chemicals. Testing results suggest the usefulness of INVDOCK as an in 
silico tool in facilitating the identification of potential therapeutic targets of the MP 
ingredients and thus providing valuable clues to the mechanisms of herbal 
medicines and their possible secondary therapeutic effects. This may greatly 
facilitate the mechanistic study of herbal medicines. Performance and applicability of 
in silico methods may be further improved by incorporation of new information from 
advances in structural genomics, proteomics, protein function, and 
pharmacokinetics. Efficiency and accuracy of in silico methods in analyzing the 
mechanisms of herbal medicines can also be enhanced from new progress in 
computational algorithms, parameters, and more accurate models of the interaction 
between a target and its binding molecules. 








The course of new drug discovery is still inefficient and costly nowadays. 
Rational drug design has been introduced to facilitate this process. The essence of 
rational drug design is the reasoned extrapolation of our knowledge of targeted 
receptors and “lead” structures to suggest novel chemical structures with defined 
characteristics as potential drugs.  
The selection of therapeutic targets to be worked with is therefore very important. 
In contemporary new drug discovery processes, it is the first stage of R&D leading to 
a new drug and directs further investigations. The appropriate selection of effective 
therapeutic targets and efficient therapeutic intervention strategies is receiving more 
and more attention. With this regard, this work explored the use of in silico 
approaches in facilitating relevant research.  
First, a comprehensive information source of known therapeutic target 
information devoted to new drug discovery will be undoubtedly helpful to the relevant 
research communities. However, existing drug target information is still scattered 
among the huge quantity of biomedical literature. Work needs to be done to collect 
and sort known drug target information to provide an easy access to relevant 
communities. As a fundamentally important task, a database of known therapeutic 
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target information, Therapeutic Target Database, was curated. A relational data 
model was designed specifically for it which aims to maximize the ability to 
accommodate future extensions and facilitate the integration of information.  
Rapid discovery of new therapeutic targets is also very important as it may not 
only introduce more efficient therapeutic targets for certain diseases, but also 
increase the flexibility in the design of novel therapeutic intervention strategies by 
exploiting the synergies between known and newly discovered targets. With known 
examples of therapeutic targets, statistical learning methods might be able to learn 
the common features of therapeutic targets and predict the drug-target like proteins 
in the human genome. This, if feasible, would greatly help the rapid discovery of 
therapeutic targets based on the human genomic data. A number of statistical 
learning methods and pre-processing techniques are explored for the application of 
drug-target like protein prediction. Among them, the support vector machine 
approach gives the best classification results which are reasonably good to facilitate 
the in-sillico genome scale drug-target screening. Performance of the statistical 
learning methods may be further improved by incorporation of new information from 
advances in pharmaceutical sciences and proteomics. The accuracy of statistical 
learning methods in prediction of drug-target like proteins can also be enhanced from 
new progress in learning algorithms, descriptors, and pre-processing techniques.  
Besides more effective therapeutic targets, delicate therapeutic intervention 
involving multiple cooperating targets may also help to improve the treatment 
efficacy. Novel therapeutic mechanisms discovered from studies of herbal medicines 
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have routinely been used in new drug discovery. With known drug target information, 
in silico approaches may also be used in the study of novel medicinal plant 
mechanisms. While a number of approaches have the potential in this application, 
our testing results on one of them, the INVDOCK approach, suggests its usefulness 
in facilitating the identification of potential therapeutic targets of MP ingredients and 
thus providing valuable clues to the mechanisms of effective herbal medicines. 
Performance and applicability of in silico methods may be further improved with new 
advances in structural genomics, proteomics, protein function, and pharmacokinetics. 
Efficiency and accuracy of in silico methods in analyzing herbal medicine 
mechanisms can also be enhanced from new progress in computational algorithms, 
parameters, and more accurate models of the interaction between a target and its 
binding molecules. 
Currently, the computer aided drug design approaches mainly focus on the 
structure properties of a drug target and its possible binder to find or design a 
chemical that could bind the target tightly. Essentially, they are based on the “lock 
and key” principle proposed by Fisher more than 100 years ago [445]. This principle 
has such a big influence on medicinal chemists and drug design experts that when a 
new drug needs to be designed, they always think of the receptors (drug targets) first, 
and then design a “key” to that receptor to treat that disease.  
However, drug designing approaches based on the “lock and key” principle have 
their innate deficiency. For example, theoretically, drug-receptor interactions are 
dynamic processes. That is to say, a drug must pass through a “cavity” to reach the 
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active site of the receptor. It means when the drug is passing the “cavity”, the 
drug-receptor complex is probably in a transition state. The structure of this transition 
complex can not yet be determined experimentally or be modeled by effective 
algorithms. Also, the kinetic process of how the drug is administrated, transported, 
metabolized and excreted is not considered. In other words, the processes prior to 
and after drug–receptor interaction have not yet been paid enough attention, which 
are also very important factors that determine the chance of finding a successful 
drug. Therefore, while the modern drug designing approaches indeed helped much 
in the research and development of new drugs, the rate of success is still low.  
Introducing the consideration of drug mechanisms into rational drug design 
becomes a popular idea among drug design experts, which is recognized as 
mechanism based drug design (MBDD). In this regard, the drug target directed in 
silico approaches discussed in this work can be viewed as part of the efforts to 
embody therapeutic mechanism based drug design. Besides drug targets, the other 
important factors affecting the success of a drug, such as its ADME profile, toxicity 
and drug-drug interaction profile, are also critical to the new drug discovery process. 
Novel approaches incorporating the consideration of these factors into the early 
stages of the drug discovery process would therefore be expected to further improve 
the research and development efficiency, which would be interesting topics that 
follow this work.
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